PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵: C12N 15/13, C07K 15/28, C12N 15/62, A61K 39/395

(11) International Publication Number:

WO 94/13806

(43) International Publication Date:

23 June 1994 (23.06.94)

(21) International Application Number:

PCT/US93/12039

A1

(22) International Filing Date:

10 December 1993 (10.12.93)

(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SF).

(30) Priority Data:

07/990,263

11 December 1992 (11.12.92) US

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.


- (71) Applicant: THE DOW CHEMICAL COMPANY [US/US]; 2030 Dow Center, Abbott Road, Midland, MI 48640 (US).
- (72) Inventors: MEZES, Peter, S.; 25 Sill Lane, Oldlyme, CT 06371 (US). GOURLIE, Brian, B.; 3713 Orchard Drive, Midland, MI 48640 (US).
- (74) Agent: ULMER, Duane, C.; The Dow Chemical Company, Patent Department, P.O. Box 1967, Midland, MI 48641-1967 (US).

(54) Title: MULTIVALENT SINGLE CHAIN ANTIBODIES

(57) Abstract

The present invention discloses multivalent single chain antibodies which have two or more biologically active antigen binding sites. The multivalent single chain antibodies are formed by using a peptide linker to covalently link two or more single chain antibodies, each single chain antibody having a variable light domain linked to a variable heavy chain domain by a peptide linker.

Schematic Representation Of Covalently & Non-Covalently Linked Single Chain Fv Multimers



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
ΑÜ	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HÜ	Hungary	NO	Norway
BG	Bulgaria	ΗE	Ireland	NZ	New Zealand
BJ	Benin	П	Italy	PL	Poland
BR	Brazil	JP	Јарап	PT	Portugal
BY	Belarus	KE	Кепуа	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic	SD	Sudan
CG	Congo		of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SI	Slovenia
CI	Côte d'Ivoire	KZ	Kazakhstan	SK	Slovakia
CM	Cameroon	LI	Liechtenstein	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Мопасо	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gabon				

MULTIVALENT SINGLE CHAIN ANTIBODIES

The present invention relates to single chain multivalent antibodies.

Antibodies are proteins belonging to a group of immunoglobulins elicited by the immune system in response to a specific antigen or substance which the body deems foreign. There are five classes of human antibodies, each class having the same basic structure. The basic structure of an antibody is a tetramer, or a multiple thereof, composed of two identical heterodimers each consisting of a light and a heavy chain. The light chain is composed of one variable (V) and one constant (C) domain, while a heavy chain is composed of one variable and three or more constant domains. The variable domains from both the light and heavy chain, designated V_L and V_H respectively, determine the specificity of an immunoglobulin, while the constant (C) domains carry out various effector functions.

Amino acid sequence data indicate that each variable domain comprises three complementarity determining regions (CDR) flanked by four relatively conserved framework regions (FR). The FR are thought to maintain the structural integrity of the variable region domain. The CDR have been assumed to be responsible for the binding specificity of individual antibodies and to account for the diversity of binding of antibodies.

As the basic structure of an antibody contains two heterodimers, antibodies are multivalent molecules. For example, the IgG classes have two identical antigen binding sites, while the pentameric IgM class has 10 identical binding sites.

Monoclonal antibodies having identical genetic parentage and binding specificity have been useful both as diagnostic and therapeutic agents. Monoclonal antibodies are routinely produced by hybridomas generated by fusion of mouse lymphoid cells with an appropriate mouse myeloma cell line according to established procedures. The administration of murine antibodies for in vivo therapy and diagnostics in humans is limited however, due to the human anti-mouse antibody response illicited by the human immune system.

Chimeric antibodies, in which the binding or variable regions of antibodies derived from one species are combined with the constant regions of antibodies derived from a different species, have been produced by recombinant DNA methodology. See, for example, Sahagen et al., J. Immunol., 137:1066-1074 (1986); Sun et al., Proc. Natl. Acad. Sci. USA, 82:214-218 (1987); Nishimura et al., Cancer Res., 47:999-1005 (1987); and Lie et al. Proc Natl. Acad. Sci. USA, 84:3439-3443 (1987) which disclose chimeric antibodies to tumor-associated antigens. Typically, the variable region of a murine antibody is joined with the constant region of a human antibody. It is expected that as such chimeric antibodies are largely human in composition, they will be substantially less immunogenic than murine antibodies.

Chimeric antibodies still carry the Fc regions which are not necessary for antigen binding, but constitute a major portion of the overall antibody structure which affects its pharmacokinetics. For the use of antibodies in immunotherapy or immunodiagnostics, is it

desirable to have antibody-like molecules which localize and bind to the target tissue rapidly and for the unbound material to quickly clear from the body. Generally, smaller antibody fragments have greater capillary permeability and are more rapidly cleared from the body than whole antibodies.

Since it is the variable regions of light and heavy chains that interact with an antigen, single chain antibody fragments (scFvs) have been created with one V_L and one V_H , containing all six CDR's, joined by a peptide linker (U.S. Patent 4,946,778) to create a V_L -L- V_H polypeptide, wherein the L stands for the peptide linker. A scFv wherein the V_L and V_H domains are orientated V_H -L- V_L is disclosed in U.S. Patent 5,132,405.

5

10

30

As the scFvs have one binding site as compared to the minimum of two for complete antibodies, the scFvs have reduced avidity as compared to the antibody containing two or more binding sites.

It would therefore be advantageous to obtain constructions of scFvs having more than one binding site to enhance the avidity of the polypeptide, and retain or increase their antigen recognition properties. In addition, it would be beneficial to obtain multivalent scFvs which are bispecific to allow for recognition of different epitopes on the target tissue, to allow for antibody-based recruitment of other immune effector functions, or allow antibody capture of a therapeutic or diagnostic moiety.

It has been found that single chain antibody fragments, each having one V_H and one V_L domain covalently linked by a first peptide linker, can be covalently linked by a second peptide linker to form a multivalent single chain antibody which maintains the binding affinity of a whole antibody. In one embodiment, the present invention is a multivalent single chain antibody having affinity for an antigen wherein the multivalent single chain antibody comprises two or more light chain variable domains and two or more heavy chain variable domains; wherein, each variable domain is linked to at least one other variable domain.

In another embodiment, the present invention is a multivalent single chain antibody which comprises two or more single chain antibody fragments, each fragment having affinity for an antigen wherein the fragments are covalently linked by a first peptide linker and each fragment comprising:

- (a) a first polypeptide comprising a light chain variable domain;
- (b) a second polypeptide comprising a heavy chain variable domain; and
- (c) a second peptide linker linking the first and second polypeptides into a functional binding moiety.

In another embodiment, the invention provides a DNA sequence which codes for a multivalent single chain antibody, the multivalent single chain antibody comprising two or more single chain antibody fragments, each fragment having affinity for an antigen wherein the fragments are covalently linked by a first peptide linker and each fragment comprising:

(a) a first polypeptide comprising a light chain variable domain;

(b) a second polypeptide comprising a heavy chain variable domain; and

(c) a second peptide linker linking the first and second polypeptides into a functional binding moiety.

The multivalent single chain antibodies allow for the construction of an antibody fragment which has the specificity and avidity of a whole antibody but are smaller in size allowing for more rapid capillary permeability. Multivalent single chain antibodies also allow for the construction of a multivalent single chain antibody wherein the binding sites can be two different antigenic determinants.

BRIEF DESCRIPTION OF THE DRAWINGS

10

15

Figure 1 illustrates covalently linked single chain antibodies having the configuration V_L -L- V_H -L- V_H (LHLH) and V_L -L- V_H -L- V_H -L- V_L (LHHL) and a noncovalently linked Fv single chain antibody (Fv2).

Figure 2 illustrates the nucleotide sequence of CC49 V_L.

Figure 3 illustrates the amino acid sequence of CC49 V_L.

Figure 4 illustrates the nucleotide sequence of CC49 V_H.

Figure 5 illustrates the amino acid sequence of CC49 V_H.

Figure 6 illustrates the nucleotide sequence and amino acid sequence of the CC49 single chain antibody LHLH in p49LHLH.

Figure 7 illustrates the nucleotide sequence and amino acid sequence of the CC49 single antibody LHHL in p49LHHL.

Figure 8 illustrates construction of plasmids pSL301 T and pSL301 HT.

Figure 9 illustrates construction of plasmid p49LHHL.

Figure 10 illustrates construction of plasmid p49LHLH.

Figure 11 illustrates the results of a competition assay using CC49 IgG, CC49 scFv2, and CC49 scFv using biotinylated CC49 IgG as competitor.

The entire teaching of all references cited herein are hereby incorporated by reference.

Nucleic acids, amino acids, peptides, protective groups, active groups and such, when abbreviated, are abbreviated according to the IUPAC IUB (Commission on Biological Nomenclature) or the practice in the fields concerned.

The term "single chain antibody fragment" (scFv) or "antibody fragment" as used herein means a polypeptide containing a V_L domain linked to a V_H domain by a peptide linker (L), represented by V_L-L-V_H. The order of the V_L and V_H domains can be reversed to obtain polypeptides represented as V_H-L-V_L. "Demain" is a segment of protein that assumes a discrete function, such as antigen binding or antigen recognition.

A "multivalent single chain antibody" means two or more single chain antibody fragments covalently linked by a peptide linker. The antibody fragments can be joined to form bivalent single chain antibodies having the order of the V_L and V_H domains as follows:

 $V_{L}-L-V_{H}-L-V_{L}-L-V_{H}-L-V_{H}-L-V_{L}$; $V_{H}-L-V_{L}-V_{H}-L-V_{L}$; or $V_{H}-L-V_{L}-V_{L}-V_{H}-L-V_{L}$. Single chain multivalent antibodies which are trivalent and greater have one or more antibody fragments joined to a bivalent single chain antibody by an additional interpeptide linker. In a preferred embodiment, the number of V_L and V_H domains is equivalent.

The present invention also provides for multivalent single chain antibodies which can be designated V_H -L- V_H -L- V_L -L- V_L or V_L -L- V_L -L- V_H -L- V_H .

5

10

15

30

Covalently linked single chain antibodies having the configuration V_L-L-V_H-L-V_L-L--V_H (LHLH) and V_L-L-V_H-L-V_H-L-V_L (LHHL) are illustrated in Figure 1. A noncovalently linked Fv single chain antibody (Fv2) is also illustrated in Figure 1.

The single chain antibody fragments for use in the present invention can be derived from the light and/or heavy chain variable domains of any antibody. Preferably, the light and heavy chain variable domains are specific for the same antigen. The individual antibody fragments which are joined to form a multivalent single chain antibody may be directed against the same antigen or can be directed against different antigens.

To prepare a vector containing the DNA sequence for a single chain multivalent antibody, a source of the genes encoding for these regions is required. The appropriate DNA sequence can be obtained from published sources or can be obtained by standard procedures known in the art. For example, Kabat et al., Sequences of Proteins of Immunological Interest 4th ed., (1991), published by The U.S. Department of Health and Human Services, discloses 30 sequences of most of the antibody variable regions which have been described to date.

When the genetic sequence is unknown, it is generally possible to utilize cDNA sequences obtained from mRNA by reverse transcriptase mediated synthesis as a source of DNA. to clone into a vector. For antibodies, the source of mRNA can be obtained from a wide range of hybridomas. See, for example, the catalogue ATCC Cell Lines and Hybridomas, American 25 Type Culture Collection, 20309 Parklawn Drive, Rockville Md., USA (1990). Hybridomas secreting monoclonal antibodies reactive with a wide variety of antigens are listed therein, are available from the collection, and usable in the present invention. These cell lines and others of similar nature can be utilized as a source of mRNA coding for the variable domains or to obtain antibody protein to determine amino acid sequence of the monoclonal antibody itself.

Variable regions of antibodies can also be derived by immunizing an appropriate vertebrate, normally a domestic animal, and most conveniently a mouse. The immunogen will be the antigen of interest, or where a hapten, an antigenic conjugate of the hapten to an antigen such as keyhole limpet hemocyanin (KLH). The immunization may be carried out conventionally with one or more repeated injections of the immunogen into the host mammal, 35 normally at two to three week intervals. Usually, three days after the last challenge, the spleen is removed and dissociated into single cells to be used for cell fusion to provide hybridomas from which mRNA can readily be obtained by standard procedures known in the art.

When an antibody of interest is obtained, and only its amino acid sequence is known, it is possible to reverse translate the sequence.

The V_L and V_H domains for use in the present invention are preferably obtained from one of a series of CC antibodies against tumor-associated glycoprotein 72 antigen

(TAG-72) disclosed in published PCT Application WO 90/04410 on May 3, 1990, and published PCT Application WO 89/00692 on January 26, 1989. More preferred are the V_L and V_H domains from the monoclonal antibody designated CC49 in PCT Publications WO 90/04410 and WO 89/00692. The nucleotide sequence (SEQ ID NO: 1) which codes for the V_L of CC49 is substantially the same as that given in Figure 1. The amino acid sequence (SEQ ID NO: 2) of the V_L of CC49 is substantially the same as that given in Figure 2. The nucleotide sequence (SEQ ID NO: 3) which codes for the V_H of CC49 is substantially the same as that given in Figure 3. The amino acid sequence (SEQ ID NO: 4) for the V_H of CC49 is substantially the same as that given in Figure 4.

present invention, it is necessary to have a suitable peptide linker. Suitable linkers for joining the V_H and V_L domains are those which allow the V_H and V_L domains to fold into a single polypeptide chain which will have a three dimensional structure very similar to the original structure of a whole antibody and thus maintain the binding specificity of the whole antibody from which antibody fragment is derived. Suitable linkers for linking the scFvs are those which allow the linking of two or more scFvs such that the V_H and V_L domains of each immunoglobulin fragment have a three dimensional structure such that each fragment maintains the binding specificity of the whole antibody from which the immunoglobulin fragment is derived. Linkers having the desired properties can be obtained by the method disclosed in U.S. Patent 4,946,778, the disclosure of which is hereby incorporated by reference.

From the polypeptide sequences generated by the methods described in the 4,946,778, genetic sequences coding for the polypeptide can be obtained.

Preferably, the peptide linker joining the V_H and V_L domains to form a scFv and the peptide linker joining two or more scFvs to form a multivalent single chain antibody have substantially the same amino acid sequence.

It is also necessary that the linker peptides be attached to the antibody fragments such that the binding of the linker to the individual antibody fragments does not interfere with the binding capacity of the antigen recognition site.

30

A preferred linker is based on the helical linker designated 205C as disclosed in Pantoliano et al. *Biochem.*, <u>30</u>, 10117-10125 (1991) but with the first and last amino acids changed because of the codon dictated by the Xho I site at one end and the Hind III site at the other. The amino acid sequence (SEQ ID NO: 5) of the preferred linker is as follows:

The linker is generally 10 to 50 amino acid residues. Preferably, the linker is 10 to 30 amino acid residues. More preferably the linker is 12 to 30 amino acid residues. Most preferred is a linker of 15 to 25 amino acid residues.

Expression vehicles for production of the molecules of the invention include plasmids or other vectors. In general, such vectors contain replicon and control sequences which are derived from species compatible with a host cell. The vector ordinarily carries a replicon site, as well as specific genes which are capable of providing phenotypic selection in transformed cells. For example, E. coli is readily transformed using pBR322 [Bolivar et al., Gene, 2, 95- (1977), or Sambrook et al., Molecular Cloning, Cold Spring Harbor Press, New York, 2nd 10 Ed. (1989)].

5

20

25

35

Plasmids suitable for eukaryotic cells may also be used. S. cerevisiae, or common baker's yeast, is the most commonly used among eukaryotic microorganisms, although a number of other strains, such as Pichia pastoris, are available. Cultures of cells derived from multicellular organisms such as SP2/0 or Chinese Hamster Ovary (CHO), which are available from the ATCC, may also be used as hosts. Typical of vector plasmids suitable for mammalian cells are pSV2neo and pSV2gpt (ATCC); pSVL and pKSV-10 (Pharmacia), pBPV-1/pML2d (International Biotechnology, Inc.).

The use of prokaryotic and eukaryotic viral expression vectors to express the genes for polypeptides of the present invention is also contemplated.

It is preferred that the expression vectors and the inserts which code for the single chain multivalent antibodies have compatible restriction sites at the insertion junctions and that those restriction sites are unique to the areas of insertion. Both vector and insert are treated with restriction endonucleases and then ligated by any of a variety of methods such as those described in Sambrook et al., supra.

Preferred genetic constructions of vectors for production of single chain multivalent antibodies of the present invention are those which contain a constitutively active transcriptional promoter, a region encoding signal peptide which will direct synthesis/secretion of the nascent single chain polypeptide out of the cell. Preferably, the expression rate is commensurate with the transport, folding and assembly steps to avoid accumulation of the 30 polypeptide as insoluble material. In addition to the replicon and control sequences, additional elements may also be needed for optimal synthesis of single chain polypeptide. These elements may include splice signals, as well as transcription promoter, enhancers, and termination signals. Furthermore, additional genes and their products may be required to facilitate assembly and folding (chaperones).

Vectors which are commercially available can easily be altered to meet the above criteria for a vector. Such alterations are easily performed by those of ordinary skill in the art in light of the available literature and the teachings herein.

Additionally, it is preferred that the cloning vector contain a selectable marker, such as a drug resistance marker or other marker which causes expression of a selectable trait by the host cell. "Host cell" refers to cells which can be recombinantly transformed with vectors constructed using recombinant DNA techniques. A drug resistance or other selectable marker is intended in part to facilitate in the selection of transformants. Additionally, the presence of a selectable marker, such as a drug resistance marker, may be of use in keeping contaminating microorganisms from multiplying in the culture medium. In this embodiment, such a pure culture of the transformed host cell would be obtained by culturing the cells under conditions which require the induced phenotype for survival.

Recovery and purification of the present invention can be accomplished using standard techniques known in the art. For example, if they are secreted into the culture medium, the single chain multivalent antibodies can be concentrated by ultrafiltration. When the polypeptides are transported to the periplasmic space of a host cell, purification can be accomplished by osmotically shocking the cells, and proceeding with ultrafiltration, antigen affinity column chromatography or column chromatography using ion exchange chromatography and gel filtration. Polypeptides which are insoluble and present as refractile bodies, also called inclusion bodies, can be purified by lysis of the cells, repeated centrifugation and washing to isolate the inclusion bodies, solubilization, such as with guanidine-HCl, and refolding followed by purification of the biologically active molecules.

10

20

The activity of single chain multivalent antibodies can be measured by standard assays known in the art, for example competition assays, enzyme-linked immunosorbant assay (ELISA), and radioimmunoassay (RIA).

The multivalent single chain antibodies of the present invention provide unique benefits for use in diagnostics and therapeutics. The use of multivalent single chain antibodies 25 afford a number of advantages over the use of larger fragments or entire antibody molecules. They reach their target tissue more rapidly, and are cleared more quickly from the body.

For diagnostic and/or therapeutic uses, the multivalent single chain antibodies can be constructed such that one or more antibody fragments are directed against a target tissue and one or more antibody fragments are directed against a diagnostic or therapeutic 30 agent.

The invention also concerns pharmaceutical compositions which are particularly advantageous for use in the diagnosis and/or therapy of diseases, such as cancer, where target antigens are often expressed on the surface of cells. For diagnostic and/or therapeutic uses, the multivalent single chain antibodies can be conjugated with an appropriate imaging or 35 therapeutic agent by methods known in the art. The pharmaceutical compositions of the invention are prepared by methods known in the art, e.g., by conventional mixing, dissolving or lyophilizing processes.

The invention will be further clarified by a consideration of the following examples, which are intended to be purely exemplary of the present invention.

ABBREVIATIONS

	BCIP	5-bromo-4-chloro-3-indoyl phosphate
	bp	base pair
5	Bis-Tris propane	<pre>(1,3-bis[tris(hydroxymethyl)-methylamino]- propane)</pre>
	BSA	bovine serum albumin
	CDR	Complementarity determining region
	ELISA	enzyme linked immunosorbent assay
40	Fv2	non-covalent single chain Fv dimer
10	IEF	isoelectric focusing
	Kbp	kilo base pair
	LB	Luria-Bertani medium
	Mab	monoclonal antibody
	MES	2-(N-Morpholino)ethane sulfonic acid
15	MW	molecular weight
	NBT	nitro blue tetrazolium chloride
	Oligo	Oligonucleotides
	PAG	polyacrylamide gel
	PAGE	polyacrylamide gel electrophoresis
20	PBS	phosphate buffered saline
	PCR	polymerase chain reaction
	pSCFV	plasmid containing DNA sequence coding for SCFV
	RIGS	radioimmunoguided surgery
	RIT	radioimmunotherapy
25	scFv	single chain Fv immunoglobulin fragment monomer
	scFv2	single chain Fv immunoglobulin fragment dimer covalently linked
	SDS	sodium dodecyl sulfate
	TBS	Tris-buffered saline
30	Tris	(Tris[hydroxymethyl]aminomethane)
	TTBS	Tween-20 wash solution
	$v_{\rm H}$	immunoglobulin heavy chain variable domain
	$v_{\mathtt{L}}$	immunoglobulin light chain variable domain

<u>Antibodies</u>

CC49: A murine monoclonal antibody specific to the human tumor-associated glycoprotein 72 (TAG-72) deposited as ATCC No. HB9459.

<u>CC49 FAB</u>: An antigen binding portion of CC49 consisting of an intact light chain linked to the N-terminal portion of the heavy chain.

<u>CC49 scFv</u>: Single chain antibody fragment consisting of two variable domains of CC49 antibody joined by a peptide linker.

CC49 Fv2: Two CC49 scFv non-covalently linked to form a dimer. The number after Fv refers to the number of monomer subunits of a given molecule, e.g., CC49 Fv6 refers to the hexamer multimers.

CC49 scFv2: Covalently-linked single chain antibody fragment consisting of two CC49 V_L domains and two V_H domains joined by three linkers. Six possible combinations for the order of linking the $V_L(L)$ and the $V_H(H)$ domains together are: LHLH, LHHL, LLHH, HLLH, and HHLL.

15 Plasmids

<u>pSCFV UHM</u>: Plasmid containing coding sequence for scFv consisting of a CC49 variable light chain and a CC49 variable heavy chain joined by a 25 amino acid linker.

<u>p49LHLH or p49LHHL</u>: Plasmids containing the coding sequence for producing CC49 scFv2 LHLH or LHHL products, respectively.

20 EXAMPLES

General Experimental

Procedures for molecular cloning are as those described in Sambrook et al.,

Molecular Cloning, Cold Spring Harbor Press, New York, 2nd Ed. (1989) and Ausubel et al.,

Current Protocols in Molecular Biology, John Wiley and Sons, New York (1992), the disclosures
of which are hereby incorporated by reference.

All water used throughout was deionized distilled water.

Oligonucleotide Synthesis and Purification

All oligonuclotides (oligos) were synthesized on either a Model 380A or a Model 391 DNA Synthesizer from Applied Biosystems (Foster City, CA) using standard β-cyanoethyl phosphoramidites and synthesis columns. Protecting groups on the product were removed by heating in concentrated ammonium hydroxide at 55°C for 6 to 15 hours. The ammonium hydroxide was removed through evaporation and the crude mixtures were resuspended in 30 to 40 μL of sterile water. After electrophoresis on polyacrylamide-urea gels, the oligos were visualized using short wavelength ultraviolet (UV) light. DNA bands were excised from the gel and eluted into 1 mL of 100 mM Tris-HCl, pH 7.4, 500 mM NaCl, 5 mM EDTA over 2 hours at 65°C. Final purification was achieved by applying the DNA to Sep-Pac™ C-18 columns (Millipore, Bedford, MA) and eluting the bound oligos with 60 percent methanol. The

solution volume was reduced to approximately 50 μL and the DNA concentration was determined by measuring the optical density at 260 nm (OD₂₆₀).

Restriction Enzyme Digests

All restriction enzyme digests were performed using Bethesda Research
Laboratories (Gaithersburg, MD), New England Biolabs, Inc. (Beverly, MA) or Boehringer
Mannheim (BM, Indianapolis, IN) enzymes and buffers following the manufacturer's
recommended procedures. Digested products were separated by polyacrylamide gel
electrophoresis (PAGE). The gels were stained with ethidium bromide, the DNA bands were
visualized using long wavelength UV light and the DNA bands were then excised. The gel slices
were placed In dialysis tubing (Union Carbide Corp., Chicago) containing 5 mM Tris, 2.5 mM
acetic acid, 1 mM EDTA, pH 8.0 and eluted using a Max Submarine electrophoresis apparatus
(Hoefer Scientific Instruments, CA). Sample volumes were reduced on a Speed Vac
Concentrator (Savant Instruments, Inc., NY). The DNA was ethanol precipitated and redissolved
in sterile water.

15 Enzyme Linked Immunosorbent Assay (ELISA)

TAG-72 antigen, prepared substantially as described by Johnson et al, Can. Res., 46, 850-857 (1986), was adsorbed onto the wells of a polyvinyl chloride 96 well microtiter plate (Dynatech Laboratories, Inc., Chantilly, VA) by drying overnight. The plate was blocked with 1 percent BSA in PBS for 1 hour at 31°C and then washed 3 times with 200 µL of PBS, 20 0.05 percent Tween-20. 25 μ L of test antibodies and 25 μ L of biotinylated CC49 (1/20,000 dilution of a 1 mg/mL solution) were added to the wells and the plate incubated for 30 minutes at 31°C. The relative amounts of TAG-72 bound to the plate, biotinylated CC49, streptavidinalkaline phosphatase, and color development times were determined empirically in order not to have excess of either antigen or biotinylated CC49, yet have enough signal to detect 25 competition by scFv. Positive controls were CC49 at 5 µg/mL and CC49 Fab at 10 µg/mL. Negative controls were 1 percent BSA in PBS and/or concentrated LB. Unbound proteins were washed away. $50\,\mu\text{L}$ of a 1:1000 dilution of streptavidin conjugated with alkaline phosphatase (Southern Biotechnology Associates, Inc., Birmingham, AL) were added and the plate was incubated for 30 minutes at 31°C. The plate was washed 3 more times. 50 µL of a 30 para-nitrophenyl-phosphate solution (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD) were added and the color reaction was allowed to develop for a minimum of 20 minutes. The relative amount of scFv2 binding was measured by optical density scanning at 404-450 nm using a microplate reader (Molecular Devices Corporation, Manlo Park, CA). Binding of the scFv2 species resulted in decreased binding of the biotinylated CC49 with a concomitant 35 decrease in color development.

SDS-PAGE and Western Blotting

Samples for SDS-PAGE analysis (20 μ L) were prepared by boiling in a non-reducing sample preparation buffer-Seprasol I (Integrated Separation Systems (ISS), Natick, MA) for

5 minutes and loaded on 10-20 percent gradient polyacrylamide Daiichi Minigels as per the manufacturer's directions (ISS).

Electrophoresis was conducted using a Mini 2-gel apparatus (ISS) at 55 mA per gel at constant current for approximately 75 minutes. Gels were stained in Coomassie Brilliant Blue R-250 (Bio-Rad, Richmond, CA) for at least 1 hour and destained. Molecular weight standards were prestained (Mid Range Kit, Diversified Biotech, Newton Center, MA) and included the following proteins: Phosphorylase b, glutamate dehydrogenase, ovalbumin, lactate dehydrogenase, carbonic amhydrase, B-lactoglobulin and cytochrome C. The corresponding MWs are: 95,500, 55,000, 43,000, 36,000, 29,000, 18,400, and 12,400, respectively.

10

When Western analyses were conducted, a duplicate gel was also run. After electrophoresis, one of the gels was equilibrated for 15-20 minutes in anode buffer #1 (0.3 M Tris-HCl pH 10.4). An Immobilon-P PVDF (polyvinylidene dichlorine) membrane (Millipore, Bedford, MA) was treated with methanol for 2 seconds, and immersed in water for 2 minutes. The membrane was then equilibrated in anode buffer #1 for 3 minutes. A Milliblot-SDE 15 apparatus (Millipore) was utilized to transfer proteins in the gel to the membrane. A drop of anode buffer #1 was placed in the middle of the anode electrode surface. A sheet of Whatman 3MM filter paper was soaked in anode buffer #1 and smoothly placed on the electrode surface. Another filter paper soaked in anode buffer #2 (25 mM tris pH 10.4) was placed on top of the first one. A sandwich was made by next adding the wetted PVDF membrane, placing the 20 equilibrated gel on top of this and finally adding a sheet of filter paper soaked in cathode buffer (25mM Tris-HCl, pH 9.4 in 40 mM glycine). Transfer was accomplished in 30 minutes using 250 mA constant current (initial voltage ranged from 8-20 volts).

After blotting, the membrane was rinsed briefly in water and placed in a dish with 20 mL blocking solution (1 percent bovine serum albumin (BSA) (Sigma, St. Louis, MO) in 25 Tris-buffered saline (TBS)). TBS was purchased from Pierce Chemical (Rockford, IL) as a preweighed powder such that when 500 mL water is added, the mixture gives a 25 mM Tris, 0.15 M sodium chloride solution at pH 7.6. The membranes were blocked for a minimum of 1 hour at ambient temperature and then washed 3 times for 5 minutes each using 20 mL 0.5 percent Tween-20 wash solution (TTBS). To prepare the TTBS, 0.5mL of Tween 20 (Sigma) 30 was mixed per liter of TBS. The probe antibody used was 20 mL biotinylated FAID14 solution (10 µg per 20 mL antibody buffer). Antibody buffer was made by adding 1 g BSA per 100 mL of TTBS. After probing for 30-60 minutes at ambient temperature, the membrane was washed 3 times with TTBS, as above.

Next, the membrane was incubated for 30-60 minutes at ambient temperature 35 with 20 mL of a 1:500 dilution in antibody buffer of streptavidin conjugated with alkaline phosphatase (Southern Biotechnology Associates, Birmingham, AL). The wash step was again repeated after this, as above. Prior to the color reaction, membranes were washed for 2 minutes in an alkaline carbonate buffer (20 mL). This buffer is 0.1 M sodium bicarbonate,

1 mM MgCl,-H,0, pH 9.8. To make up the substrate for alkaline phosphatase, nitroblue tetrazolium (NBT) chloride (50 mg, Sigma) was dissolved in 70 percent dimethylformamide. 5-Bromo-4-chloro-3-indoyl phosphate (BCIP) (25 mg, Sigma) was separately dissolved in 100 percent dimethylformamide. 5-Bromo-4-chloro-3-indoyl phosphate (BCIP) 25 mg, Sigma) was separately dissolved in 100 percent dimethylformamide. These solutions are also commercially available as a Western developing agent sold by Promega. For color development, 120 µL of each were added to the alkaline solution above and allowed to react for 15 minutes before they were washed from the developed membranes with water. **Biotinylated FAID14**

FAID14 is a murine anti-idiotypic antibody (IgG2a, K isotype) deposited as ATCC No. CRL 10256 directed against CC49. FAID14 was purified using a Nygene Protein A affinity column (Yonkers, NY). The manufacturer's protocol was followed, except that 0.1 M sodium citrate, pH 3.0 was used as the elution buffer. Fractions were neutralized to pH \sim 7 using 1.0 M Tris-HCl pH 9.0. The biotinylation reaction was set up as follows. FAID14 (1 mg, 100 µL in 15 water) was mixed with 100 μL of 0.1 M Na,CO, pH 9.6. Biotinyl-ε-amino-caproic acid N-hydroxy succinimide ester (Biotin-X-NHS) (Calbiochem, LaJolla, CA) (2.5 mg) was dissolved in 0.5 mL dimethylsulfoxide. Biotin-X-NHS solution (20 µL) was added to the FAID14 solution and allowed to react at 22°C for 4 hours. Excess biotin and impurities were removed by gel filtration, using a Pharmacia Superose 12 HR10/30 column (Piscataway, NJ). At a flow rate of 20 0.8 mL/min, the biotinylated FAID14 emerged with a peak at 16.8 min. The fractions making up this peak were pooled and stored at 4°C and used to detect the CC49 idiotype as determined by the CC49 V₁ and V₂ CDRs.

Isoelectric Focusing (IEF)

10

Isoelectric points (pl's) were predicted using a computer program called PROTEIN-25 -TITRATE, available through DNASTAR (Madison, WI). Based on amino acid composition with an input sequence, a MW value is given, in addition to the pl. Since Cys residues contribute to the charge, the count was adjusted to 0 for Cys, since they are all involved in disulfide bonds.

Experimentally, pl's were determined using Isogel agarose IEF plates, pH range 3-10 (FMC Bioproducts, Rockland, ME). A Biorad Bio-phoresis horizontal electrophoresis cell 30 was used to run the IEF, following the directions of both manufacturers. The electrophoresis conditions were: 500 volts (limiting), at 20 mA current and 10 W of constant power. Focusing was complete in 90 min. IEF standards were purchased from Biorad; the kit included phycocyanin, β -lactoglobulin B, bovine carbonic anhydrase, human carbonic anhydrase, equine myoglobin, human hemoglobins A and C, 3 lentil lectins and cytochrome C, with pl values of 4.65, 5.10, 6.00, 6.50, 7.00, 7.10 and 7.50, 7.80, 8.00, and 8.20 and 9.60, respectively. Gels were stained and destained according to the directions provided by FMC.

Quantitation of CC49 Antibody Species

All purified CC49 antibodies including the IgG, scFv2 species and the monomeric scFv were quantitated by measuring the absorbence of protein dilutions at 280 mm using matching 1.0 cm pathlength quartz cuvettes (Hellma) and a Perkin-Elmer UV/VIS Spectrophotometer, Model 552A. Molar absorptivities (E_m) were determined for each antibody by using the following formula:

 $E_m = (number Trp) X 5,500 + (number Tyr) X 1,340 + (number (Cys)2) X 150 + (number Phe) X 10$

The values are based on information given by D. B. Wetlaufer, *Advances in Protein Chemistry*, 10 17, 375-378).

High Performance Liquid Chromatography

All high performance liquid chromatography (HPLC) was performed for CC49 scFv2 purification using an LKB HPLC system with titanium or teflon tubing throughout. The system consists of the Model 2150 HPLC pump, model 2152 controller, UV CORD SII model 2238 detection system set at an absorbence of 276 nm and the model 2211 SuperRac fraction collector.

PCR Generation of Subunits

All polymerase chain reactions (PCR) were performed with a reaction mixture consisting of: 150 picograms (pg) plasmid target (pSCFVUHM); 100 pmoles primers; 1 μL

Perkin-Elmer-Cetus (PEC, Norwalk, CT) Ampli-Taq polymerase; 16 μL of 10 mM dNTPs and 10 μL of 10X buffer both supplied in the PEC kit; and sufficient water to bring the volume to total volume to 100 μL. The PCR reactions were carried out essentially as described by the manufacturer. Reactions were done in a PEC 9600 thermocycler with 30 cycles of: denaturation of the DNA at 94°C for 20 to 45 sec, annealing from between 52 to 60°C for 0.5 to 1.5 min., and elongation at 72°C for 0.5 to 2.0 min. Oligonucleotide primers were synthesized on an Applied Biosystems (Foster City, CA) 380A or 391 DNA synthesizer and purified as above.

Ligation reactions using 100 ng of vector DNA and a corresponding 1:1 stoichiometric equivalent of insert DNA were performed using a Stratagene (La Jolla, CA) T4

DNA ligase kit following the manufacturer's directions. Ligation reactions (20 µL total volume) were initially incubated at 18°C and allowed to cool gradually overnight to 4°C.

Transformations

Transformations were performed utilizing 100 µL of Stratagene E. coli AG1 competent cells (Stratagene, La Jolla, CA) according to the directions provided by the manufacturer. DNA from the ligation reactions (1-5 µL) were used. After the transformation step, cells were allowed to recover for 1 hr in Luria broth (LB) at 37°C with continuous mixing and subsequently plated onto either 20 µg/mL chloramphenicol containing (CAM 20) Luria agar for pSCFVUHM, p49LHLH or p49LHHL or 100 µg/mL ampicillin (AMP 100) Luria agar plates

(LB-AMP 100) for clones containing the plasmid pSL301 or subsequent constructions derived from pSL301.

Screening of E. coli Clones

Bacterial plasmids were isolated from LB broth culture containing the appropriate drug to maintain selection pressure using Promega (Madison, WI) Magic mini-prep plasmid preparation kits. The kit was used per the manufacturer's specifications.

Plasmid Constructions

15

Two plasmids, designated p49LHLH and p49LHHL, were constructed to produce multivalent single chain antibodies. The host cell containing p49LHLH produced a polypeptide which can be designated by V_L -L- V_H -L- V_L -L- V_H where V_L and V_H are the light and heavy cahin variable regions of CC49 antibody and linker (L) is a 25 amino acid linker having the sequence (SEQ ID NO: 5).

The host cell containing p49LHHL produced a polypeptide which can be designated by V_L -L- V_H -L- V_H -L- V_L where V_L and V_H are the light and heavy chain variable domains of the CC49 antibody and L is a peptide linker having the amino acid sequence indicated above.

The nucleotide sequence (SEQ ID NO: 6) and amino acid sequence (SEQ ID NO: 7)

20 of the CC49 V_L-L-V_H-L-V_L-L-V_H (p49LHLH) are given in Figure 6. The nucleotide sequence (SEQ ID NO: 8) and amino acid sequence (SEQ ID NO: 9) of the CC49 V_L-L-V_H-L-V_H-L-V_L (p49LHHL) are given in Figure 7.

Construction of pSL301 HT

The construction of pSL301 HT is illustrated in Figure 8. The Bacillus lichiformis

penicillinase P (penP) terminator sequence was removed from the plasmid designated pSCFV UHM by a 45 minute digest with Nhe I and BamH I, excised from a 4.5 percent polyacrylamide gel after electrophoresis, electroeluted, ethanol precipitated and ligated into the same sites in the similarly prepared vector: pSL301 (Invitrogen, San Diego, CA). A procedure for preparing pSCFV UHM is given is U.S. patent application Ser. No. 07/935,695 filed August 21, 1992, the disclosure of which is hereby incorporated by reference. In general, pSCFV UHM contains a nucleotide sequence for a penP promoter; a unique Nco I restriction site; CC49 V_L region; Hind III restriction site; a 25 amino acid linker; a unique a Xho I restriction site; CC49 V_H region; Nhe I restriction site; penP terminator; and BamH I restriction site (see, Figure 8). The penP promoter and terminator are described in Mezes, et al. (1983), J. Biol.

Chem., 258, 11211-11218 (1983).

An eliquot of the ligation reaction (3 µL) was used to transform competent *E. coli* AG1 cells which were plated on LB-AMP100 agar plates and grown overnight. Potential clones containing the penP terminator insert were screened using a Pharmacia (Gaithersburg, MD) T7

PCT/US93/12039 WO 94/13806

Ouickprime 32P DNA labeling kit in conjunction with the microwave colony lysis procedure outlined in Buluwela et al., Nucleic Acid Research, 17, 452 (1989). The probe, which was the penP-Nhe I-BamH I terminator fragment itself was prepared and used according to the directions supplied with the Quickprime kit. A clone which was probe positive and which contained the 207 base pair inserts from a BamH I and Nhe I digest (base pairs (bp) 1958 to 2165, Figure 6) was designated pSL301 T and chosen to construct pSL301 HT which would contain the nucleotide sequence for CC49 V_H. The reason the Nhe I-BamH I penP terminator was placed into pSL301 was to eliminate the Eco47 III restriction endonuclease site present in the polylinker region between its Nhe I and BamH I sites. This was designed to accommodate the subsequent build-up of the V_L and V_H domains where the Eco47 III site needed to be unique for the placement of each successive V domain into the construction. As each V domain was added at the Eco47 III-Nhe I sites, the Eco47 III was destroyed in each case to make the next Eco47 III site coming in on the unique insert.

The V_H sequence was made by PCR with oligos 5' SCP1 and 3'oligo SCP5 using pSCFV UHM as the target for PCR amplification. The DNA sequence for SCP1 (SEQ ID NO: 10) and SCP5 (SEQ ID NO: 11) are as follows:

SCP1: 5'-TAAA CTC GAG GTT CAG TTG CAG CAG -3'

20

35

SCP5: 5'-TAAA GCT AGC ACCA AGC GCT TAG TGA GGA GAC GGT GAC TGA GGT-3' The underlined portion indicates the endonuclease restriction sites.

The amplified V_H DNA was purified from a 4 percent PAG, electroeluted ethanol precipitated and dissolved in 20 µL water. The V_H sequence was digested with Xho I and Nhe I restriction enzymes and used as the insert with the pSL301 T vector which had been digested with the same restriction enzymes and subsequently purified. A standard ligation reaction was done and an aliquot (4 µL) used to transform competent E. coli AG1 cells. The transformed cells were plated onto LB AMP100 agar plates. Candidate clones were picked from a Nhe I and Xho I digest screen that revealed that the CC49V_H insert had been obtained.

DNA sequencing was performed to verify the sequence of the CC49V_H with United States Biochemical (USB) (Cleveland, Ohio) Sequence kit and sequencing primers pSL301SEQB (a 21 bp sequencing primer which annealed in the pSL301 vector 57 bp upstream $_{30}$ from the Xho I site) and CC49VHP, revealed clones with the correct CC49V_H sequence in pSL301HT. This plasmid was used as the starting point in the construction of both pSL301-HHLT and pSL301-HLHT. The sequencing oligos used are shown here.

The nucleotide sequence of pSL301SEQ B (SEQ ID NO: 12) and CC49V_H (SEQ ID No: 13) are as follows:

> pSL301SEQB: 5'-TCG TCC GAT TAG GCA AGC TTA-3' CC49VHP: 5'-GAT GAT TTT AAA TAC AAT GAG-3'

Example 1 p49LHHL Construction

20

30

Using pSL301 HT (5 µg) as the starting material, it was digested with Eco47 III and Nhe I and the larger vector fragment was purified. A CC49V_H insert fragment was generated by PCR using SCP6C as the 5' oligo and SCP5 as the 3' oligo. The nucleotide sequence (SEQ ID NO: 14) of SCP6B is as follows:

SCP6B: 5'- TAAA <u>TGC GCA</u> GAT GAC GCA AAG AAA GAC GCA GCT AAA AAA GAC GAT GCC AAA AAG GAT GAC GCC AAG AAA GAT CTT GAG GTT CAG TTG CAG CAG TCT-G'

The oligo SCP6B also contains part of the coding region for the linker (bp 8-76 of SEQ ID 10 NO: 14). The portion of the oligo designed to anneal with the CC49VH target in pSCFV UHM is from bp77-90 in SEQ ID NO: 14.

The underlined sequence corresponds to the Fsp I site. The resulting PCR insert was purified, digested with Fsp I and Nhe I and used in a ligation reaction with the pSL301 HT Eco47 III-Nhe i vector (Figure 7). Competent E. coli AG1 cells were used for the transformation $_{15}$ of this ligation reaction (3 μ L) and were plated on LB-AMP100 agar plates. Two clones having the correct size Xho I-Nhe I insert representative of the pSL301 HHT product were sequenced with the oligo SQP1 and a single clone with the correct sequence (nucleotides 1124-1543 of Figure 7) was chosen for further construction. The nucleotide sequence of SQP1 (SEQ ID NO: 16) is as follows:

SQP1: 5'-TG ACT TTA TGT AAG ATG ATG T-3'

The final linker-V_L subunit (bp 1544-1963, Figure 7) was generated using the 5'oligo, SCP7b and the 3' oligo, SCP8a, using pSCFV UHM as the target for the PCR. The nucleotide sequence of SCP7b (SEQ ID NO: 17 is as follows:

SCP7b: 5'-TAAA TGC GCA GAT GAC GCA AAG AAA GAC GCA GCT AAA AAA GAC GAT GCC AAA AAG GAT GAC GCC AAG AAA GAT CTT GAC ATT GTG ATG TCA CAG TCT 25

The underlined nucleotides correspond to an Fsp I site. The nucleotide sequence of SCP8a (SEQ ID NO: 18) is as follows:

> SCP8a: 5'-TAAA GCT AGC TTT TTA CTT AAG CAC CAG CTT GGT CCC-3'

The first set of underlined nucleotides correspond to an Nhe I site, while the other corresponds to an Afl II site. Nucleotides 8-76 of SCP70 code for the linker (nucleotides 1544-1612 of Figure 7) while nucleotides 77-99 which anneal to the V_L correspond to 1613-1635 of Figure 7. The primer SCP8a has a short tail at its 5' end, a Nhe I restriction site, a stop codon, an AfI II restriction site and the last 21 bases of the V_L. After Fsp I and Nhe I digestion, this resulting 420 bp insert was purified and ligated into the Nhe I and Eco47 III sites of the purified pSL301HHT vector, candidate clones were screened with Nhe I and Xho I, the correct size insert verified and sequenced with 49LFR2(-) and SQP1 to confirm the newly inserted sequence in pSL301HHLT. The nucleotide sequence (SEQ ID NO: 19) is as follows:

49LFR2(-): 5'-CTG CTG GTA CCA GGC CAA G-3'

The plasmid pSL301HHLT was digested with Xho I and Nhe I, purified, and the resulting 1179 bp V_H -linker- V_H -linker- V_L segment ligated into pSCFV UHM, which had been cut with the same restriction enzymes and the larger vector fragment purified, to form p49LHHL. The ligation reaction (4 μ L aliquot) was used to transform competent E. coli AG1 cells (Stratagene) and plated onto LBCAM20 agar plates. A single clone which had a plasmid with the correct restriction enzyme map was selected to contain p49LHHL. The p49LHHL contains a penP promoter and a nucleotide sequence for the CC49 multivalent single chain antibody scFv2:

 V_L -L- V_H -L- V_L or CC49 scFv2 (LHHL).

Example 2: p49LHLH Construction

10

15

The construction of p49LHLH is schematically represented in Figure 11. A linker- V_L subunit was generated with the 5' oligo SCP7b and the 3'oligo SCP9.

SCP9: 5'-TAA AGC TAG CAC CAA GCG CTT AGT TTC AGC ACC AGC TTG GTC CCA G-3'

The SCP7b oligo (nucleotides 8-76) codes for the linker in Figure 6 (corresponding to nucleotides 1124-1192) and annealed to the pSCFV UHM target for the PCR (nucleotides 77-99) corresponding to nucleotides 1193-1215 of the V₁ in Figure 6.

underlined nucleotides) which are restriction sites needed for making the pSL301HLT ready to accept the next V domain. Nucleotides 18-23 of SCP9 correspond to nucleotides 1532-1537 of Figure 6 (coding for the first 2 amino acids of the linker), while nucleotides 24-46 correspond to nucleotides 1508-1531 of Figure 6 which was also the annealing region for SCP9 in the PCR. The plasmid pSL301 HT was digested with Eco47 III and Nhe I and the larger vector fragment was purified for ligation with the linker-CC49V_L DNA insert fragment from the PCR which had been treated with Fsp I and Nhe I and purified. The ligation mixture (3 µL) was used to transform *E. coli* AG1 competent cells and one colony having the correct Xho I-Nhe I size fragment was sequenced using the oligo PENPTSEQ2. The nucleotide sequence (SEQ. ID NO. 21) is as follows:

5'-TTG ATC ACC AAG TGA CTT TAT G-3'

The sequencing results indicated that there had been a PCR error and deletion in the resulting pSL301HT clone. A five base deletion, corresponding to nucleotides 1533-1537 as seen in Figure 6 had been obtained and nucleotide 1531 which should have been a T was actually a G, as determined from the DNA sequence data. The resulting sequence was

5'...G AAGC GCT T...etc.

where the underlined sequence fortuitously formed an Eco47 III site. The

35 AGCGCT sequence in Figure 6, would correspond to nucleotides 1530, 1531, 1532, 1538, 1539

and 1540. This error was corrected in the next step, generating pSL301 HLHT, by incorporating the 5 base deletion at the end of oligo SCP6C.

SCP6C: 5'-TAAGCGCTGATGATGCTAAGAAGGACGCCGCAAAAAA **GGACGACGCAAAAAAAGATGATGCAAAAAAGGATCTGG** AGGTTCAGTTGCAGCAGTCTGAC-3'

The underlined sequence in SCP6c corresponds to an Eco47 III site. SCP6C was used as the 5' oligo, with SCP10 as the 3' oligo in a PCR to generate a linker CC49 $\rm V_L$ segment. 5 The nucleotide sequence (SEQ ID NO: 23) is as follows:

SCP10: 5'TTG TGC TAG CTT TTT ATG AGG AGA CGG TGA CTG AGG TT-3'

The underlined sequence in SCP10 corresponds to the Nhe I site found at nucleotides 1958-1963 in Figure 6. The PCR insert was digested this time only with Nhe I and purified. The vector (pSL301 HLT) was digested at the Eco47 III site (that had been formed) and Nhe I and purified. The insert and vector were ligated and an aliquot (3 µL) used to transform competent E. coli AG1 cells. This was plated on LB-AMP100 plates and candidate clones screened with Xho I and Nhe I. Three clones having the correct size DNA were obtained. Two of these clones were sequenced using the oligo 49VLCDR3(+) and SQP1. The nucleotide 15 sequence (DWQ ID NO: 24 of 49VLCDR3(+) is as follows:

49VLCDR3(+):

20

5'-CAG CAG TAT TAT AGC TAT-3'

One clone, with the correct sequence was obtained and the sequence from nucleotides 1533 to 1963 in Figure 6 were verified, giving a correct pSL301 HLHL clone.

To generate the final plasmid, p49LHLH for expression in E. coli, pSL301 HLHT (5 µg) was digested with Nhe I and Xho I, and the smaller insert fragment containing the V_H-L-V_L-L-V_H sequence purified. It was ligated with the larger purified vector fragment from a digest of pSCFV UHM (5 µg) with Xho I and Nhe I. An aliquot of the ligation mix (4 µL) was used to transform competent E. coli AG1 cells. The transformation mix was plated on LB-CAM20 25 plates, and a representative clone for p49 LHLH was selected on the basis of a correct restriction enzyme map (see Figure 10) and biological activity toward TAG-72.

Example 3: Purification of CC49 scFv2 LHLH and LHHL Covalently Linked Dimers For the purification of the CC49 covalently linked single chain dimers, (scFv2), E. coli periplasmic fractions were prepared from 1.0 L overnight cultures of both p49LHLH and 30 p49LHHL. Briefly, the culture was divided into 4 X 250 mL portions and centrifuged at 5,000 rpm for 10 minutes in a Sorvall GS-3 rotor. The pelleted cells were washed and resuspended in 100 mL each of 10 mM Tris-HCl pH 7.3 containing 30 mM NaCl. The cells were again pelleted and washed with a total of 100 mL 30 mM Tris-HCl pH 7.3 and pooled into one tube. To this, 100 mL of 30 mM Tris-HCl pH 7.3 containing 40 percent w/v sucrose and 2.0 mL of ूर् 10 mM EDTA pH 7.5 was added. The mixture was eapt at room temperature, with occasional shaking, for 10 minutes. The hypertonic cells were then pelleted as before. In the next step, the shock, the pellet was quickly suspended in 20 mL ice cold 0.5 mM MgCl₂ and kept on ice for 10 minutes, with occasional shaking. The cells were pelleted as before and the supernatant

containing the *E. coli* periplasmic fraction was clarified further by filtration through a 0.2 µm Nalge (Rochester, NY) filter apparatus and concentrated in Amicon (Danvers, MA) Centriprep 30 and Centricon 30 devices to a volume of less than 1.0 mL.

The concentrated periplasmic shockates from either the p49LHLH or p49LHHL clones were injected onto a Pharmacia (Piscataway, NJ) Superdex 75 HR 10/30 HPLC column that had been equilibrated with PBS. At a flow rate of 0.5 mL/minute, the product of interest, as determined by competition ELISA, had emerged between 21 through 24 minutes. The active fractions were pooled, concentrated as before and dialyzed overnight using a system 500 Microdialyzer Unit (Pierce Chemical) against 20 mM Tris-HCl pH 7.6 with 3-4 changes of buffer and using an 8,000 MW cut-off membrane. The sample was injected on a Pharmacia Mono Q HR 5/5 anion exchange HPLC column. A gradient program using 20 mM Tris-HCl pH 7.6 as buffer A and the same solution plus 0.5 M NaCl as buffer B was employed at a flow rate of 1.5 mL/min. The products of interest in each case, as determined by competition ELISA, emerged from the column between 3 and 4 minutes. Analysis of the fractions at this point on 15 duplicate SDS-PAGE gels, one stained with Coomassie Brilliant Blue R-250 and the other transferred for Western analysis (using biotinylated FAID 14 as the probe antibody) revealed a single band at the calculated molecular weight for the scFv2 (LHLH or LHHL) species at 58,239 daltons. The active fractions were in each case concentrated, dialysed against 50 mM MES pH 5.8 overnight and injected on a Pharmacia Mono S HR 5/5 cation exchange column. The two 20 fractions of interest from this purification step, as determined by SDS-PAGE and ELISA, fractions 5 and 6, eluted just before the start of the gradient, so they had not actually bound to the column. Fractions 5 and 6 were consequently pooled for future purification.

A Mono Q column was again run on the active Mono S fractions but the buffer used was 20 mM Tris-HCl, pH 8.0 and the flow rate was decreased to 0.8 mL/minute. The products emerged without binding, but the impurity left over from the Mono S was slightly more held up, so that separation did occur between 5 and 6 minutes. After this run, the products were homogeneous and were saved for further characterization.

| Soelectric Focusing

The isoelectric points (pl) of the constructs was predicted using the DNASTAR

(Madison, WI) computer program Protein-titrate. Based on amino acid composition, a MW and pl value was calculated.

Experimentally, pls were determined using FMC Bioproducts (Rockland, ME) Isogel IEF plates, pH range 3-10. A Biorad (Richmond, CA) electrophoresis unit was used to run the IEF, following the directions of both manufacturers. The electrophoresis conditions were as follows: 500 V (limiting) at 20 mA and at 10 W of constant power. Focusing was complete in 90 minutes. Biorad IEF standards included phycocyanin, beta lactoglobulin B, bovine carbonic anhydrase, human carbonic anhydrase, equine myoglobulin, human hemoglobins A and C, 3 lentil lectin, and cytochrome C with pI value of 4.65, 5.10, 6.00, 6,50, 7.00, 7.50, 7.8, 8.00, 8.20

and 9.6, respectively. Gels were stained and destained according to directions provided by FMC. The DNASTAR program predicted values of 8.1 for the pl for both scFv2 species. A single, homogeneous band for the pure products was observed on the gel at pl values for both at 6.9.

Purified CC49 antibodies such as the IgG, scFv2 (LHLH and LHHL) were quantitated by measuring the absorbence spectrophotometrically at 280 nm. Molar absorbtivity values, $\epsilon_{\rm M}$, were determined for each using the formula cited above by Wetlaufer.

Based on the amino acid composition, the E^{0.1%} (280 nanometers) values for CC49 IgG, CC49 scFv2 LHLH, CC49 scFv2 LHHL and CC49 scFv were 1.49, 1.65, 1.65 and 1.71, respectively.

10 Example 4

15

35

Relative activities of the CC49 scFv2 species LHLH and LHHL, were compared with the IgG and a monomer scFv form with a FLAG peptide at the COOH terminus.

Percent competition was determined from the ELISA data by the following equation:

Zero competition - sample reading (OD405-450 nm) x 100 zero competition - 100 percent competition

The "zero competition" value was determined by mixing (1:1) one percent BSA with the biotinylated CC49 (3 X 10-14 moles) while the 100 percent competition value was based on a 5 μ g/mL sample of CC49 IgG mixed with the biotinylated CC49 IgG. The data are presented in Figure 11. Absorbence values for the samples were measured at 405 nm - 450 nm.

The average of triplicate readings was used. Initially samples (25 µL) were applied to the TAG-72 coated microliter plates at 1.0 X 10-10 moles of binding sites/mL. Biotinylated CC49 (4 µg/µL diluted 1:20,000 - used 25 µL) diluted the samples by a factor of 2. Serial dilutions (1:2) were performed. Both forms of the scFv2 are approximately equivalent to the IgG (see Figure 11). In a separate experiment, a CC49 scFv monomer was compared to a Fab fragment,

both of which are monovalent and these were also shown to be equivalent in their binding affinity for TAG-72. These results indicate that both forms of the covalently linked dimers have 2 fully functional antigen binding sites. This is the same increase in avidity as observed with the whole IgG, relative to a monomeric species.

These data also indicate that the scFv2 molecules, like their CC49 IgG parent are candidates for immunotherapeutic applications, but with the benefit of increased capillary permeability and more rapid biodistribution pharmacokinetics. The advantage should allow multiple injections of compounds of the present invention and give higher tumor:tissue ratios in immunotherapeutic treatment regimens for cancer treatment, relative to the existing IgG molecules.

Other embodiments of the invention will be apparent to those skilled in the art from a consideration of this specification or practice of the invention disclosed herein. It is

intended that the specification and examples be considered as exemplary only, with the true scope and spirit of the invention being indicated by the following claims.

1. A mutivalent single chain antibody which comprises two or more single chain antibody fragments each fragment having affinity for an antigen wherein the fragments are covalently linked by a first peptide linker and each fragment comprising:

- (a) a first polypeptide comprising a light chain variable domain;
- (b) a second polypeptide comprising a heavy chain variable domain; and
- (c) a second peptide linker linking the first and second polypeptides into a functional binding moiety.
- 2. The multivalent single chain antibody of Claim 1 wherein the first peptide linker has the amino and sequence

Leu Ser Ala Asp Asp Ala Lys Lys Asp Ala Ala Lys Lys Asp Asp Ala Lys Lys Asp Asp Ala Lys Lys Asp Leu.

- 3. The multivalent single chain antibody of Claim 1 wherein the light chain variable region has an amino acid sequence substantially the same as that of Figure 3 and the heavy chain variable region has an amino acid sequence substantially the same as that of Figure 5.
 - 4. The multivalent single chain antibody of Claim 1 wherein the first and second peptide linkers have an amino acid sequence which is substantially the same.
- 5. A DNA sequence which codes for a mutivalent single chain antibody, the multivalent single antibody comprising two or more single chain antibody fragments, each
 fragment having affinity for an antigen wherein the fragments are covalently linked by a first peptide linker and each fragment comprising:
 - (a) a first polypeptide comprising a light chain variable domain;
 - (b) a second polypeptide comprising a heavy chain variable domain; and
 - (c) a second peptide linker linking the first and second polypeptides into a functional binding moiety.
 - 6. The DNA sequence of Claim 5 wherein the sequence coding for the first polypeptide is substantially the same as that of Figure 2 and the sequence coding for the second polypeptide is substantially the same as that of Figure 3.

30

25

5

10

35

FIGURE 1




FIGURE 2

GAC ATT GTG ATG TCA CAG TCT CCA TCC TCC CTA CCT GTG TCA
GTT GGC GAG AAG GTT ACT TTG AGC TGC AAG TCC AGT CAG AGC
CTT TTA TAT AGT GGT AAT CAA AAG AAC TAC TTG GCC TGG TAC
CAG CAG AAA CCA GGG CAG TCT CCT AAA CTG CTG ATT TAC TGG
GCA TCC GCT AGG GAA TCT GGG GTC CCT GAT CGC TTC ACA GGC
AGT GGA TCT GGG ACA GAT TTC ACT CTC TCC ATC AGC AGT GTG
AAG ACT GAA GAC CTG GCA GTT TAT TAC TGT CAG CAG TAT TAT
AGC TAT CCC CTC ACG TTC GGT GCT GGG ACC AAG CTG GTG
AAG

FIGURE 3

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Pro Val Ser Val Gly Glu Lys Val Thr Leu Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ala Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Ser Ser Val Lys Thr Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Val Leu Lys

FIGURE 4

GAG GTT CAG TTG CAG CAG TCT GAC GCT GAG TTG GTG AAA CCT
GGG GCT TCA GTG AAG ATT TCC TGC AAG GCT TCT GGC TAC ACC
TTC ACT GAC CAT GCA ATT CAC TGG GTG AAA CAG AAC CCT GAA
CAG GGC CTG GAA TGG ATT GGA TAT TTT TCT CCC GGA AAT GAT
GAT TTT AAA TAC AAT GAG AGG TTC AAG GGC AAG GCC ACA CTG
ACT GCA GAC AAA TCC TCC AGC ACT GCC TAC GTG CAG CTC AAC
AGC CTG ACA TCT GAG GAT TCT GCA GTG TAT TTC TGT ACA AGA
TCC CTG AAT ATG GCC TAC TGG GGT CAA GGA ACC TCA GTC
GTC TCC TCA

FIGURE 5

Glu Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His Ala Ile His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile Gly Tyr Phe Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Val Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Thr Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser

FIGURE

DNA AND AMINO ACID SEQUENCE OF CC49 VL-L-VH-L-VL-L-VH

46	ħ6	142	190	238	286	334	382	430	478
TCC	AAA	ATT	TTA	AGA	ACG	Leu TTA	Pro	Lys AAG	40 Ala GCC
သသ	GAA	TAC	CAA	GAA	GAG		Ser	Cys	Leu TTG
CTT	TCC	GAC	TAC	GTG GTG	AGG	Leu TTG	Gln CAG	Ser	Tyr
TCA	CCT	TTC AAA	CTG AAA GAT CGT ACG	ATA ATA	990	Gly	Ser	Leu	Asn
CCA	TTT	TTC	CGT	0 000	AAA		val Met	20 I Thr I	Lys AAG
ECOR I	TCA TCA	AAT ACT	GAT	GTA	TTC	Ala GCC	Val GTG	Val	Gly Asn Gln Lys GGT AAT CAA AAG
TGA		AAT	AAA	ACT	ATA	Ala GCA	Ile ATJ	Gly Glu Lys Val GGC GAG AAG GTT	Asn AAT
CGA	AGG	TAT		AAC	CAA PR2-	Thr	VL Asp GAC	Glu GAG	Gly
TAT CAT CGA	GAA ACG AGG	TAC ATA	AGT CGG	PENPR1- AAC AGC CAT AAC	ATC AAT CAA	Pro	Ala GCC	Gly	Ser
TAT		TAC	AGT		ATC	Leu Leu CTA TTG	Met ATG	Val GTT	Tyr
GCT	GTG	TCT	TTG	TCA	ACG	Leu	Nco I VL A Ala Met Ala Asp	Val Ser Val GTG TCA GTT	30 Leu Leu Tyr Ser CTT TTA TAT AGT
TTG ACA	ຽວວ	AAA	TGT	TGT	GTT	Tyr	Pr	Val	Leu
	TCC	TTT	TGA	GAT	CTG	Lys	Gln	Pro	Ser
TGT	TIG	GCA	ATT	CGT	CAT	-22 Met ATG	Ala GCC	Leu	Gln
TCA	CAT	GTT	AAG	TIT	CII	TTG	Ala GCT	Ser TCC	Ser
5,-c	GTT	ACG	TGT	TTG	GTG	ATT	Leu	Ser	Ser

FIGURE 6 (Cont. (2))

526	574	622	670	718	766
Trp TGG	Gly	Asp GAC	Phe	120 Lys AAA	Lys AAG
Tyr	Ser	Glu GAA	Thr	Ala GCG	Lys Aaa
Ile	70 G1y GGC	Thr	Leu	Asp Gat	Ala GCT
Leu CTG	Thr	Lys AAG	Pro	Asp Gac	Asp Gat
Leu CTG	Phe TTC	Val GTG	100 Tyr TAT	Ala GCG	Asp Gac
Lys AAA	Arg	Ser AGT	Ser	Ser AGT	Lys
Pro CCT	Asp Gat	Ser AGC	Tyr TAT	Leu	130 Lys
Ser	Pro	Ile	Tyr TAT	Hind Lys AAG (Ala
Gln CAG	Val GTC	80 Ser TCC	Gln CAG	Leu CTG	Asp
Gly GGG	Gly GGG	Leu CIC	Gln CAG	Val GTG	Asp Gat
Pro	Ser	Thr		110 Leu CIG	Lys AAG
Lys AAA	G1u GAA	Phe TTC	Tyr	Lys AAG	Lys AAG
Gln CAG	60 Arg Agg	Asp GAT	Tyr Tat	Thr	Ala GCG
Gln CAG	Ala GCT	Thr	Val GTT	Gly	Ala GCT
Tyr TAC	Ser	61y 666	90 Ala GCA	Ala GCT	Asp
Trp TGG	Ala GCA	Ser	Leu CTG	Gly GGT	Lys

FIGURE 6 (Cont. (3))

814	862	910	958	1006	1054
Pro	Thr	Glu GAA	GAG Glu GAG	Thr	Tyr
Lys C	Phe	Leu	AAT Asn AAT	Ser	Val GTG
150 Val rg AA	Thr	Gly	200 TAC TAC	Ser	230 Ala GCA
ည် ၁၈	Tyr	Gln	AAA Lys Aaa	Ser	Ser
Glu So Tj	Gly	180 Glu GAA	TTT Phe TTT	Lys AAA	Asp GAT
Ala YI G	Ser	Pro	GAT Asp GAT	Asp Gac	Glu GAG
Asp IC GC	Ala GCT	Asn	GAT Asp GAT	210 Ala GCA	Ser
Ser T G	Lys AAG	Gln CAG	CC49VHP- Pro Gly Asn CCC GGA AAT	Thr	Thr
Gln NG TC	160 Cys TGC	Lys AAA	30491 Gly GGA	Leu	Leu
Gln G C	Ser	Val GTG	Pro CCC CCC	Thr ACA	Ser
ည် သို့	Ile	Trd	190 Ser TCT	Ala GCC	Asn AAC
Gln IG TJ	Lys AAG	His	Phe	Lys AAG	Leu
140 Val	Val GTG	Ile ATT	Tyr	Gly	220 Gln CAG
VH II Glu GG GJ	Ser	Ala GCA	Gly	Lys AAG	Val GTG
xpo Crea	Ala GCT	170 His CAT	Ile ATT	Phe TTC	Tyr
VH Xho I 140 Asp Leu Glu Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro GAC CTC GAG GTT CAG TTG CAG TCT GAC GCT GAG TTG GTG AAA CCT	G1y GGG	Asp GAC	17. 166	Arg AGG	Ala GCC

FIGURE 6 (Cont. (4))

	1102	1150	1198	1246	1294	1342
	Ser	Ala GCT	280 11e ATT	Lys	Asn	Pro
	Thr	Ala GCA	VL Asp GAC	Glu GAG	Gly	Ser
	G Gly GGA	Asp	Leu	Gly GGC	310 Ser AGT	Gln
	CAA Gln CAA	Lys Aaa	Asp Gat	Val GTT	Tyr TAT	G1y GGG
	667 613 661	260 Lys AAG	Lys Aaa	Ser	Leu TTA	Pro CCA
	777 775 766	Ala GCA	Lys Aag	Val GTG	Leu	Lys AAA
	TAC Tyr TAC	Asp Gac	Ala GCC	290 Pro CCT	Ser AGC	Gln
	900 Ala 900	Asp Gat	Asp Gac	Leu	Gln CAG	Gln
240	ATG Met ATG	Ala GCA	Asp Gat	Ser	Ser	320 Tyr TAC
	AAT Asn AAT	Ser AGC	Lys AAG	Ser	Ser	ir TGG
	Le G	Leu	270 Lys AAA	Pro	Lys AAG	Ala GCC
	NH49 Ser TCC	Ser	Ala GCC	Ser	Cy s	Leu TTG
	VH49J- G Arg Ser Leu AGA TCC CTG	Ser	asp gat	Gln	300 Ser AGC	Tyr
	Thr	Val GTC	Asp Gac	Ser	Leu TTG	Asn AAC
	Cys	250 Thr ACC	Lys AAA	Met ATG	Thr	Lys AAG
	Phe TTC	Val GTC	Lys AAA	Val GTG	Val GTT	Gln

FIGURE 6 (Cont. (5))

1678	1630	1582	1534	1486	1438	1390
440 Ala GCT	Asp	Lys	Leu	TAT Tyr TAT	360 Ser AGC	Asp GAT
Lys AAG	Ser	Ala GCA	Lys AAG	TAT Tyr TAT	Ile ATC	Pro
Cys TGC	Gln CAG	Asp GAC	390 Leu CTG	CAG Gln CAG	Ser	Val GTC
Ser	Gln CAG	Asp GAC	Val GTG	CAG Gln CAG	Leu	Gly
Ile	420 Leu TTG	A G	Leu	13+- Cys TGT	Thr	340 Ser TCT
Lys AAG	Gln CAG	Lys Aaa	r Lys I	LCDF Tyr TAC	Phe TTC	G1u GAA
Val GTG	Val GTT	Ala GCA	Thr	370 49VLCDR3+- Tyr Tyr Cys TAT TAC TGT	Asp Gat	Arg AGG
Ser	VH Glu GAG	Ala GCC	G1y GGG	Val GTT	Thr	Ala GCT
Ala GCT	Leu CTG	400 Asd Gac	Ala GCT	Ala GCA	61y 666	Ser
Gly GGG	Asp Gat	Lys AAG	Gly GGT	Leu	Ser	Ala GCA
430 Pro CCT	Lys AAG	Lys AAG	Phe TTC	Asp Gac	350 Gly GGA	Trd TGG
Lys AAA	Lys AAA	Ala GCT	Thr Acg	Glu GAA	Ser AGT	Tyr TAC
Val GTG	Ala GCA	Asp Gat	380 Leu CTC	Thr	Gly	Ile ATT
Leu TTG	Asp Gat	I Asp Gat	Pro	Lys AAG	Thr	Leu
G1u GAG	410 Asp Gat	Sco47 III Ser Ala Asp AGC GCT GAT	TAT Tyr TAT	Val GTG	Phe TTC	330 Leu CTG
Ala	AAG	Ser Ser NGC	Ser	Ser	Arg GC	AAA

FIGURE 6 (Cont. (6))

1726	1774	1822	1870	. 1918	1966
Asn	Asp GAT	Ala GCA	Ser	520 Tyr TAC	GAT
Gln	Asn AAT	Thr	Thr ACA	Ala GCC	I AGC
Lys AAA	470 Gly GGA	Leu CTG	Leu CTG	Met ATG	Nhe
Val GTG	Pro	Thr ACA	Ser AGC	Asn AAT	AAA
Trp TGG	Ser	Ala GCC	500 Asn AAC	Leu CTG	*** TAA
His	Phe TTT	Lys AAG	Leu	Ser	Ser
450 Ile ATT	Tyr TAT	Gly	Gln CAG	Arg Aga	530 Ser TCC
Ala GCA	Gly GGA	Lys AAG	Val GTG	Thr ACA	Val GTC
His	Ile ATT	480 Phe TTC	Tyr TAC	Cys TGT	Thr
Asp Gac	Trp TGG	Arg Agg	Ala GCC	Phe TTC	Val GTC
Thr	G1u GAA	Glu GAG	Thr	510 Tyr TAT	Ser
Phe TTC	Leu	Asn AAT	Ser AGC	Val GTG	Thr
Thr	#60 Gly GGC	Tyr	Ser	Ala GCA	Gly
Tyr	Gln CAG	Lys Aaa	Ser	Ser	Gln
Gly	Glu GAA	Phe TTT	490 Lys AAA	Asp Gat	Gly GGT
Ser	Pro	Asp Gat	Asp GAC	Glu GAG	Trp TGG

FIGURE 6 (Cont. (7))

2014	2062	2110	2158	2165
ecr 1	rti	ACC	ATT	
CTT GGT GAT CAA GCT GAA CCA CTA GTT	ATC ATT GTC CGG CAA TGG TGT GGG CTT TTT TTG TTT TCT ATC TTT	AGG 1	AAA	
GAT	TCT	GAA	GAC	
GGT	TTT	79 990 9	TGT	
CTT GGT GAT GAA CCA CTA	TIG	CTG	GAT	
TCA AGT AGT	TIT	GGT	TTG	
GTC AAA ACA TCA TGT TAC ATA AAG TCA SQP1- TGT AGT AGA ATG TAT TTC AGT PENPTSEQ2- G TAT TTC AGT	CTT	CAT GTG AAG AAA AAC GGG AAA ATC GGT CTG	TCA TAG GCG AAT GGG TTG GAT TGT GAC	
ATA TAT TAT	999	AAA	AAT	
TAC ATG	TGT	999	೮೦೮	
TCT AGA SEQ2	TGG	AAC	TAG	
TCA AGT	CAA	AAA	TCA	
ACA TGT	550	AAG	AAA	
AAA)P 1-	GTC	GTG	TCG	_
GTC SC	ATT	CAT	TTG	6-3
TCC	ATC	GAT	GGG TIT ITG ICG AAA	BamH I
GAA	CAT	AAA	999	Bar

FIGURE

DNA AND AMINO ACID SEQUENCE OF CC49 VL-L-VH-L-VL

9#	76	142	190	238	286	334	382	430
100	AAA	ATT	TTA	AGA	ACG TG	Leu TTA	Pro	Lys AAG
၁၁၁	GAA	TAC	CAA	GAA GAA	GAG	Leu TTA	Ser TCT	Cys 1GC
CII	TCC	GAC	TAC	GTG GTG	AGG	Leu TIG	Gln CAG	Ser
TCA	CCT	AAA	ACG	ATA ATA	000 000	Gly	Ser	Leu TTG
CCA	TTT	rīc	CGT	999 999	AAA TTT	Ala GCT	Met	20 Thr ACT
EGOR I TGA ATT	TCA TCA	ACT :	GAT	GTA	TIC	Ala GCC	Val GTG	
Eoc		AAT	AAA	ACT	ATA TAT	Ala GCA	Ile ATT	Glu Lys Val GAG AAG GTT
Cla I CAT CGA	AGG	TAT	CTG	RAC	AAT CAA PENPR2-	Thr	VL Asp Gac	Glu GAG
CAT	ACG	ATA	550	R1- CAT	AAT PENF	Pro	Ala GCC	
TAT	GAA	TAC	AGT	PENPR1-	ATC	Leu Leu CTA TTG	Nco I Ala Met GCC ATG	Ser Val Gly TCA GTT GGC
GCT	GTG	TCT	TIG	TCA	ACG	Leu CTA	Nec Ala GCC	Ser
ACA	ರಿಬ	AAA	TGT	TGT	GIT	Tyr TAC	Pro	Val GTG
TTG	TCC	TTT	TGA	GAT	CTG	Lys AAA	Gln	Pro
TGT	TTG	GCA	ATT	CGT	CAT	-22 Met ATG	Ala GCC	Leu
TCA	CAT	GTT	AAG	TIT	CTT	TTG	Ala GCT	10 Ser TCC
5c	GIT	ACG	TGT	TTG	GTG	ATT	Leu	Ser

FIGURE 7 (Cont. (2))

478	526	574	622	670	718	766
Ala GCC	Trp TGG	Gly GGA	Asp GAC	Phe TTC	120 Lys AAA	Lys
Leu TIG	Tyr	Ser AGT	Glu GAA	Thr	Ala GCG	Lys AAA
Tyr	Ile	70 G1y GGC	Thr	Leu	Asp Gat	Ala GCT
Asn AAC	Leu	Thr	Lys AAG	77 000	Asd Gac	asp gat
Lys AAG	Leu	Phe TTC	Val GTG	100 Tyr TAT	Ala GCG	Asp GAC
	Lys AAA	Arg	Ser AGT	Ser AGC	Ser AGT	Lys
Asn AAT	Pro	Asp Gat	Ser AGC	Tyr TAT	Hind III Lys Leu Ser AAG CTT AGT	130 Lys AAG SEQ
Gly	Ser	Pro	Ile ATC	Tyr TAT	Hind Lys AAG	Ala GCT 7L(-)
Ser AGT	Gln	Val GTC	80 Ser TCC	Gln	Leu	Asp GAC TMNV
Tyr TAT	G1y GGG	Gly GGG	Leu	Gln CAG	Val GTG	Asp GAT CTA
30 Leu TTA	Pro CCA	Ser	Thr	Cys	110 Leu CTG	Lys AAG TTC
Leu	Lys AAA	Glu GAA	Phe TTC	Tyr	Lys	Lys AAG TTC
Ser AGC	Gln CAG	60 Arg Agg	Asp Gat	Tyr	Thr	Ala GCG CGC
Gln CAG	Gln CAG	Ala GCT	Thr	Val GTT	GIY	Ala GCT CGA
Ser	Tyr	Ser	G1y GGG	90 Ala GCA	Ala GCT	Asp GAT CTA
Ser		Ala GCA	Ser	Leu CTG	Gly GGT	Lys AAG TTC

FIGURE 7 (Cont. (3))

814	862	910	958	1006	1054	1102
Pro CCT	ž H	n Y	00 a0	រួម	۲H	44
7.0	Thr	Glu GAA	200 GAG Glu GAG	Thr	Tyr TAT	Ser
Lys AAA	Phe TTC	Leu	AAT Asn AAT	Ser	Val GTG	Thr
150 Val GTG	Thr	G1y GGC	TAC Tyr TAC	Ser	230 Ala GCA	G Gly GGA
Leu TTG	Tyr	Gln CAG	AAA Lys Aaa	Ser	Ser	CAA Gin CAA
Glu	GIV	180 Glu GAA	TTT Phe TTT	Lys AAA	Asp Gat	GGT Gly GGT
Ala GCT	Ser	Pro	GAT Asp GAT	Asp	Glu GAG	166 175 166
Asp Gac	Ala GCT	Asn	GAT Asp GAT	210 Ala GCA	Ser	TAC Tyr TAC
Ser	Lys AAG	Gln CAG	/HP- Asn AAT	Thr	Thr	GCC Ala GCC
Gln	160 Cys TGC	Lys	30497 G19 GGA	Leu	Leu	240 ATG Met ATG
Gln CAG	Ser	Val GTG	CC49VHP- Pro Gly Asn CCC GGA AAT	Thr	Ser AGC	AAT Asn AAT
Leu TTG	Ile ATT	Trd	190 Ser TCT	Ala GCC	Asn	J- G Leu CIG
Gln	Lys AAG	H1s CAC	Phe TTT	Lys AAG	Leu	VH49J- G Arg Ser Leu AGA TCC CTG
140 Val GTT	Val	Ile ATT	Tyr	GIY	220 Gln CAG	Arg AGA
va I Glu GAG	Ser	Ala GCA	Gly GGA	Lys AAG	Val	Thr
Xho Leu CTC	Ala GCT	170 His Cat	Ile	Phe TTC	Tyr	Cys TGT
Asp GAC	Gly	Asp GAC	Tro	Arg Agg	Ala GCC	Phe TTC

FIGURE 7 (Cont. (4))

1150	1198	1246	1294	1342	1390	1438	1486
Ala GCT	280 Val GTT	Val	Ile Att	Tyr	Gly	360 Gln CAG	Arg Aga
Ala / GCA (VH Glu GAG	Ser	Ala GCA	Gly GGA	Lys AAG	Val GTG	Thr
Asp A	Leu	Ala	310 His CAT	Ile	Phe TTC	Tyr	Cys
Lys /	Asp Gat	GIY	Asp GAC	Tro	Arg Agg	Ala GCC	Phe TTC
260 Lys I AAG /	Lys AAA	Pro	Thr	Glu GAA	340 G1u GAG	Thr	Tyr
Ala I GCA	Lys AAG	Lys AAA	Phe	Leu	Asn AAT	Ser AGC	Val GTG
Asp A	Ala GCC	290 Val GTG	Thr	GIY	Tyr	Ser	370 Ala GCA
Asp A	Asp	Leu TIG	Tyr	Gln CAG	Lys AAA	Ser	Ser
Ala A	Asp Gat	Glu GAG	GIY	320 Glu GAA	Phe TTT	Lys AAA	Asp Gat
Ser A	Lys AAG	Ala GCT	Ser	Pro	Asp Gat	asp gac	Glu
Leu S CTA /	270 Lys Aaa	Asp GAC	Ala GCT	Asn	Asp Gat	350 Ala GCA	Ser
Ser I	Ala GCC	Ser	Lys AAG	Gln	Asn	Thr	Thr ACA
Ser S	Asp Gat	Gln	300 Cys 16C	Lys	Gly GGA	Leu	Leu CTG
Val S	Asp Gac	Gln CAG	Ser	Val GTG	Pro	Thr	Ser
250 Thr V	Lys Aaa	Leu TTG	Ile ATT	Trp	330 Ser TCT	Ala GCC	Asn
Val I	Lys	Gln CAG	Lys	HIS	Phe TTT	Lys AAG	Leu

FIGURE 7 (Cont. (5))

1534	1582	1630	1678	1726	1774	1822
Ser	Asp	Gln	440 Ser Agc	Tyr TAC	Ile	Gly
Val GTC	Asp GAC	Ser	Leu TTG	Asn AAC (2(-)	Leu	Thr
390 Thr ACC	Lys AAA	Met ATG	Thr	Lys AAG 19LFF	470 Leu CIG	Phe TIC
Val GTC	Lys	Val GTG	Val GTT	Gln Lys Asn 7 CAA AAG AAC 7 49LFR2(-)-	Lys AAA	Arg
Ser	Ala GCT	420 Ile ATT	Lys AAG	Asn AAT	Pro	Asp GAT
Thr	Ala GCA	VL Asp Gac	Glu GAG	Gly GGT	Ser	Pro
Gly	Asp GAC	Leu	Gly GGC	450 Ser Agt	Gln CAG	Val
Gln	Lys AAA	Asp GAT	Val GTT	Tyr TAT	Gly GGG	G1y GGG
Gly	400 Lys AAG	Lys Aaa	Ser	Leu TTA	Pro	480 Ser TCT
Trp TGG	Ala GCA	Lys Aag	val GTG	Leu CTT	Lys AAA	Glu GAA
Tyr	Asp GAC	Ala GCC	430 Pro CCT	Ser AGC	Gln CAG GTC	Arg Agg
Ala GCC	Asp Gat	Asp Gac	Leu	Gln CAG	Gln CAG GTC	Ala GCT
380 Met ATG	Ala GCA	Asp Gat	Ser	Ser AGT	460 Tyr TAC ATG	Ser
Asn	Ser	Lys AAG	Ser	Ser	Trp TGG ACC	Ala GCA
Leu	Leu	410 Lys AAA	Pro	Lys AAG	Ala GCC CGG	Trp TGG
Ser	Ser	Ala	Ser	Cys	Leu TIG AAC	Tyr

FIGURE 7 (Cont. (6))

1918 1966 2014 2110 2158 2155	CTC GAT GCT ACC ACC	Fro CCC CAA GTT ATC AGG	GEN TYP TYP Ser TYP B CAG TAT CAG TAT TAT AGC TAT CAG TAA AAA GCT A TTC AGT GAA CCA CTA CTT GGT GAT CTTC AGT GAT CTTC AGT CTG CGG GAA A ATC GGT CTG CGG GAA A GGG TTG GAT TGT TCT A CTG CGG GAA A GGG TTG GAT TGT GAC A CTG CGG GAA A ATC GGT CTG CGT CTG CGG GAA A ATC GGT CTG CTG CGG GAA A ATC GGT CTG CTG CTG CGG GAA A ATC GGT CTG CTG CTG CTG CTG CTG CTG CTG C	Ner AGC GGT CCA TTT TGT	TAT TAA TAA TAA TAA TAA TAA TAA GAA GAA	TYT TAT LYS AAGT AGT TIT TIT TIT TIT TIT TIT TIT TIT TIT T	GGG GGG	GGIC CAC CAC GGC GGC AAA	Cys TGT CTG CTG 1GT GGG	Tyr Tyr TAT TAC Thr Lys ACC AAG ENPTSEQ2 CAA TGG AAA AAC TCA TAG	Tyr TAT TCA TCA CAA TCA	ACA AGG CGG CGG CGG CGG CGG CGG CGG CGG	Ala GCA GTC GTC	Leu CTG GGT GGT SC CAT TTG	Asp GAC TTC TCC ATC ATC ATC	Glu GAA ACG GAA AAA AAA Bam
1870	Thr	Lys	Val GTG	Ser AGT	500 Ser AGC	Ile ATC	Ser Ile	CTC	Thr	Phe TTC	Asp Gat	Thr	Gly GGG	Ser	490 Gly GGA	Ser AGT





FIGURE 9




2. Ligate with Fsp I and Nhe I treated CC49 V_H PCR product

1. Digest with Eco47 III and Nhe I.

Isolate vector fragment.


2. Ligate with Fsp I and Nhe I treated CC49 V, PCR product.




pecry Urea 6.0 Mbp

1. Digest pSL301 HHLT with Nhe I and Xho I. isolate HHL fragment.

2. Digest pSCFV-UHM with Xho I and Nhe I isolate vector fragment and ligate with insert.





Ž

E0047 III

PCR target was pSCFV-UHM





FIGURE 11



INTERNATIONAL SEARCH REPORT

Intern al Application No

PCT/US 93/12039 A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C12N15/13 C07K15/28 C12N15/62 A61K39/395 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 5 C12N C07K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Category ' Citation of document, with indication, where appropriate, of the relevant passages WO,A,91 19739 (CELLTECH LIMITED) 26 1,5 X December 1991 2-4.6 Υ see example 1 CANCER RESEARCH 3,6 vol. 52, no. 12 , 15 June 1992 , PHILADELPHIA, PA, USA pages 3402 - 3408 T.YOKATA ET AL. 'Rapid tumour penetration of a single-chain Fv and comparison with other immunoglobulin forms' see page 3403, column 1, paragraph 4 Further documents are listed in the continuation of box C. X Patent family members are listed in annex. X Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-"O" document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled other means in the art. document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report **27 -**04- 1994 25 March 1994 Authorized officer Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,

Fax: (+31-70) 340-3016

.1

Cupido, M

INTERNATIONAL SEARCH REPORT

Intern: 1 Application No
PCT/US 93/12039

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BIOCHEMISTRY vol. 30, no. 42 , 22 October 1991 , EASTON, PA US pages 10117 - 10125 M.W.PANTOLIANO ET AL. 'Conformational stability, folding and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escherichia coli' cited in the application see page 10120, column 1, paragraph 2	2,4
X	EP,A,O 506 124 (TANOX BIOSYSTEMS, INC.) 30 September 1992 see example 4	1,5
Ρ,Χ	WO,A,93 11161 (ENZON, INC.) 10 June 1993 see figure 19A	1,3-6

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern al Application No
PCT/US 93/12039

Patent document cited in search report	Publication date	Patent memb		Publication date
WO-A-9119739	26-12-91	AU-A- EP-A- GB-A- JP-T-	7983191 0486652 2250995 5502039	07-01-92 27-05-92 24-06-92 15-04-93
EP-A-0506124	30-09-92	AU-B- AU-A- JP-A-	640863 1299292 5117164	02-09-93 15-10-92 14-05-93
WO-A-9311161	10-06-93	AU-A-	3178993	28-06-93



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵:

C12N 15/13, C07K 15/28, C12N 15/62,
A61K 39/395

(11)

(11) International Publication Number:

WO 94/13806

(43) International Publication Date:

23 June 1994 (23.06.94)

(21) International Application Number:

PCT/US93/12039

(22) International Filing Date:

10 December 1993 (10.12.93)

(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, CE)

(30) Priority Data:

07/990,263

11 December 1992 (11.12.92) US

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(71) Applicant: THE DOW CHEMICAL COMPANY [US/US]; 2030 Dow Center, Abbott Road, Midland, MI 48640 (US).

(72) Inventors: MEZES, Peter, S.; 25 Sill Lane, Oldlyme, CT 06371 (US). GOURLIE, Brian, B.; 3713 Orchard Drive, Midland, MI 48640 (US).


(74) Agent: ULMER, Duane, C.; The Dow Chemical Company, Patent Department, P.O. Box 1967, Midland, MI 48641-1967 (US).

(54) Title: MULTIVALENT SINGLE CHAIN ANTIBODIES

(57) Abstract

The present invention discloses multivalent single chain antibodies which have two or more biologically active antigen binding sites. The multivalent single chain antibodies are formed by using a peptide linker to covalently link two or more single chain antibodies, each single chain antibody having a variable light domain linked to a variable heavy chain domain by a peptide linker.

Schematic Representation Of Covalently & Non-Covalently Linked Single Chain Fv Multimers



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

ΑT	Austria	GB	United Kingdom	MR	Mauritania
ΑÜ	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic	SD	Sudan
CG	Congo		of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SI	Slovenia
Cl	Côte d'Ivoire	KZ	Kazakhstan	SK	Slovakia
CM	Cameroon	LI	Liechtenstein	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Vict Nam
GA	Gabon		-		

MULTIVALENT SINGLE CHAIN ANTIBODIES

The present invention relates to single chain multivalent antibodies.

Antibodies are proteins belonging to a group of immunoglobulins elicited by the immune system in response to a specific antigen or substance which the body deems foreign. There are five classes of human antibodies, each class having the same basic structure. The basic structure of an antibody is a tetramer, or a multiple thereof, composed of two identical 'heterodimers each consisting of a light and a heavy chain. The light chain is composed of one variable (V) and one constant (C) domain, while a heavy chain is composed of one variable and three or more constant domains. The variable domains from both the light and heavy chain, designated V_L and V_H respectively, determine the specificity of an immunoglobulin, while the constant (C) domains carry out various effector functions.

Amino acid sequence data indicate that each variable domain comprises three complementarity determining regions (CDR) flanked by four relatively conserved framework regions (FR). The FR are thought to maintain the structural integrity of the variable region domain. The CDR have been assumed to be responsible for the binding specificity of individual antibodies and to account for the diversity of binding of antibodies.

As the basic structure of an antibody contains two heterodimers, antibodies are multivalent molecules. For example, the IgG classes have two identical antigen binding sites, while the pentameric IgM class has 10 identical binding sites.

Monoclonal antibodies having identical genetic parentage and binding specificity have been useful both as diagnostic and therapeutic agents. Monoclonal antibodies are routinely produced by hybridomas generated by fusion of mouse lymphoid cells with an appropriate mouse myeloma cell line according to established procedures. The administration of murine antibodies for in vivo therapy and diagnostics in humans is limited however, due to the human anti-mouse antibody response illicited by the human immune system.

Chimeric antibodies, in which the binding or variable regions of antibodies derived from one species are combined with the constant regions of antibodies derived from a different species, have been produced by recombinant DNA methodology. See, for example, Sahagen et al., *J. Immunol.*, 137:1066-1074 (1986); Sun et al., *Proc. Natl. Acad. Sci. USA*, 82:214-218 (1987); Nishimura et al., *Cancer Res.*, 47:999-1005 (1987); and Lie et al. *Proc Natl. Acad. Sci. USA*, 84:3439-3443 (1987) which disclose chimeric antibodies to tumor-associated antigens. Typically, the variable region of a murine antibody is joined with the constant region of a human antibody. It is expected that as such chimeric antibodies are largely human in composition, they will be substantially less immunogenic than murine antibodies.

Chimeric antibodies still carry the Fc regions which are not necessary for antigen binding, but constitute a major portion of the overall antibody structure which affects its pharmacokinetics. For the use of antibodies in immunotherapy or immunodiagnostics, is it

desirable to have antibody-like molecules which localize and bind to the target tissue rapidly and for the unbound material to quickly clear from the body. Generally, smaller antibody fragments have greater capillary permeability and are more rapidly cleared from the body than whole antibodies.

Since it is the variable regions of light and heavy chains that interact with an antigen, single chain antibody fragments (scFvs) have been created with one V_L and one V_H , containing all six CDR's, joined by a peptide linker (U.S. Patent 4,946,778) to create a V_L -L- V_H polypeptide, wherein the L stands for the peptide linker. A scFv wherein the V_L and V_H domains are orientated V_H -L- V_L is disclosed in U.S. Patent 5,132,405.

5

10

30

As the scFvs have one binding site as compared to the minimum of two for complete antibodies, the scFvs have reduced avidity as compared to the antibody containing two or more binding sites.

It would therefore be advantageous to obtain constructions of scFvs having more than one binding site to enhance the avidity of the polypeptide, and retain or increase their antigen recognition properties. In addition, it would be beneficial to obtain multivalent scFvs which are bispecific to allow for recognition of different epitopes on the target tissue, to allow for antibody-based recruitment of other immune effector functions, or allow antibody capture of a therapeutic or diagnostic moiety.

It has been found that single chain antibody fragments, each having one V_H and one V_L domain covalently linked by a first peptide linker, can be covalently linked by a second peptide linker to form a multivalent single chain antibody which maintains the binding affinity of a whole antibody. In one embodiment, the present invention is a multivalent single chain antibody having affinity for an antigen wherein the multivalent single chain antibody comprises two or more light chain variable domains and two or more heavy chain variable domains; wherein, each variable domain is linked to at least one other variable domain.

In another embodiment, the present invention is a multivalent single chain antibody which comprises two or more single chain antibody fragments, each fragment having affinity for an antigen wherein the fragments are covalently linked by a first peptide linker and each fragment comprising:

- (a) a first polypeptide comprising a light chain variable domain;
- (b) a second polypeptide comprising a heavy chain variable domain; and
- (c) a second peptide linker linking the first and second polypeptides into a functional binding moiety.

In another embodiment, the invention provides a DNA sequence which codes for
a multivalent single chain antibody, the multivalent single chain antibody comprising two or
more single chain antibody fragments, each fragment having affinity for an antigen wherein
the fragments are covalently linked by a first peptide linker and each fragment comprising:

(a) a first polypeptide comprising a light chain variable domain;

(b) a second polypeptide comprising a heavy chain variable domain; and

(c) a second peptide linker linking the first and second polypeptides into a functional binding moiety.

The multivalent single chain antibodies allow for the construction of an antibody fragment which has the specificity and avidity of a whole antibody but are smaller in size allowing for more rapid capillary permeability. Multivalent single chain antibodies also allow for the construction of a multivalent single chain antibody wherein the binding sites can be two different antigenic determinants.

BRIEF DESCRIPTION OF THE DRAWINGS

10

15

Figure 1 illustrates covalently linked single chain antibodies having the configuration $V_L-L-V_H-L-V_H$ (LHLH) and $V_L-L-V_H-L-V_H-L-V_L$ (LHHL) and a noncovalently linked Fv single chain antibody (Fv2).

Figure 2 illustrates the nucleotide sequence of CC49 V_L.

Figure 3 illustrates the amino acid sequence of CC49 V_L .

Figure 4 illustrates the nucleotide sequence of CC49 $V_{\rm H}$.

Figure 5 illustrates the amino acid sequence of CC49 V_H.

Figure 6 illustrates the nucleotide sequence and amino acid sequence of the CC49 single chain antibody LHLH in p49LHLH.

Figure 7 illustrates the nucleotide sequence and amino acid sequence of the CC49 single antibody LHHL in p49LHHL.

Figure 8 illustrates construction of plasmids pSL301 T and pSL301 HT.

Figure 9 illustrates construction of plasmid p49LHHL.

Figure 10 illustrates construction of plasmid p49LHLH.

Figure 11 illustrates the results of a competition assay using CC49 IgG, CC49 scFv2, and CC49 scFv using biotinylated CC49 IgG as competitor.

The entire teaching of all references cited herein are hereby incorporated by reference.

Nucleic acids, amino acids, peptides, protective groups, active groups and such, when abbreviated, are abbreviated according to the IUPAC IUB (Commission on Biological Nomenclature) or the practice in the fields concerned.

The term "single chain antibody fragment" (scFv) or "antibody fragment" as used herein means a polypeptide containing a V_L domain linked to a V_H domain by a peptide linker (L), represented by V_L-L-V_H. The order of the V_L and V_H domains can be reversed to obtain polypeptides represented as V_H-L-V_L. "Domain" is a segment of protein that assumes a discrete function, such as antigen binding or antigen recognition.

A "multivalent single chain antibody" means two or more single chain antibody fragments covalently linked by a peptide linker. The antibody fragments can be joined to form bivalent single chain antibodies having the order of the V_L and V_H domains as follows:

 $V_L-L-V_H-L-V_L-L-V_H$; $V_L-L-V_H-L-V_L$; $V_H-L-V_L-L-V_H-L-V_L$; or $V_H-L-V_L-L-V_H$. Single chain multivalent antibodies which are trivalent and greater have one or more antibody fragments joined to a bivalent single chain antibody by an additional interpeptide linker. In a preferred embodiment, the number of V_L and V_H domains is equivalent.

The present invention also provides for multivalent single chain antibodies which can be designated V_H-L-V_H-L-V_L or V_L-L-V_L-L-V_H-L-V_H.

5

10

15

30

Covalently linked single chain antibodies having the configuration V_L-L-V_H-L-V_L-L--V_H (LHLH) and V₁-L-V_H-L-V_H-L-V_L (LHHL) are illustrated in Figure 1. A noncovalently linked Fv single chain antibody (Fv2) is also illustrated in Figure 1.

The single chain antibody fragments for use in the present invention can be derived from the light and/or heavy chain variable domains of any antibody. Preferably, the light and heavy chain variable domains are specific for the same antigen. The individual antibody fragments which are joined to form a multivalent single chain antibody may be directed against the same antigen or can be directed against different antigens.

To prepare a vector containing the DNA sequence for a single chain multivalent antibody, a source of the genes encoding for these regions is required. The appropriate DNA sequence can be obtained from published sources or can be obtained by standard procedures known in the art. For example, Kabat et al., Sequences of Proteins of Immunological Interest 4th ed., (1991), published by The U.S. Department of Health and Human Services, discloses 20 sequences of most of the antibody variable regions which have been described to date.

When the genetic sequence is unknown, it is generally possible to utilize cDNA sequences obtained from mRNA by reverse transcriptase mediated synthesis as a source of DNA to clone into a vector. For antibodies, the source of mRNA can be obtained from a wide range of hybridomas. See, for example, the catalogue ATCC Cell Lines and Hybridomas, American 25 Type Culture Collection, 20309 Parklawn Drive, Rockville Md., USA (1990). Hybridomas secreting monoclonal antibodies reactive with a wide variety of antigens are listed therein, are available from the collection, and usable in the present invention. These cell lines and others of similar nature can be utilized as a source of mRNA coding for the variable domains or to obtain antibody protein to determine amino acid sequence of the monoclonal antibody itself.

Variable regions of antibodies can also be derived by immunizing an appropriate vertebrate, normally a domestic animal, and most conveniently a mouse. The immunogen will be the antigen of interest, or where a hapten, an antigenic conjugate of the hapten to an antigen such as keyhole limpet hemocyanin (KLH). The immunization may be carried out conventionally with one or more repeated injections of the immunogen into the host mammal, normally at two to three week intervals. Usually, three days after the last challenge, the spleen is removed and dissociated into single cells to be used for cell fusion to provide hybridomas from which mRNA can readily be obtained by standard procedures known in the art.

When an antibody of interest is obtained, and only its amino acid sequence is known, it is possible to reverse translate the sequence.

The V_L and V_H domains for use in the present invention are preferably obtained from one of a series of CC antibodies against tumor-associated glycoprotein 72 antigen

(TAG-72) disclosed in published PCT Application WO 90/04410 on May 3, 1990, and published PCT Application WO 89/00692 on January 26, 1989. More preferred are the V_L and V_H domains from the monoclonal antibody designated CC49 in PCT Publications WO 90/04410 and WO 89/00692. The nucleotide sequence (SEQ ID NO: 1) which codes for the V_L of CC49 is substantially the same as that given in Figure 1. The amino acid sequence (SEQ ID NO: 2) of the V_L of CC49 is substantially the same as that given in Figure 2. The nucleotide sequence (SEQ ID NO: 3) which codes for the V_H of CC49 is substantially the same as that given in Figure 3. The amino acid sequence (SEQ ID NO: 4) for the V_H of CC49 is substantially the same as that given in Figure 4.

present invention, it is necessary to have a suitable peptide linker. Suitable linkers for joining the V_H and V_L domains are those which allow the V_H and V_L domains to fold into a single polypeptide chain which will have a three dimensional structure very similar to the original structure of a whole antibody and thus maintain the binding specificity of the whole antibody from which antibody fragment is derived. Suitable linkers for linking the scFvs are those which allow the linking of two or more scFvs such that the V_H and V_L domains of each immunoglobulin fragment have a three dimensional structure such that each fragment maintains the binding specificity of the whole antibody from which the immunoglobulin fragment is derived. Linkers having the desired properties can be obtained by the method disclosed in U.S. Patent 4,946,778, the disclosure of which is hereby incorporated by reference.

From the polypeptide sequences generated by the methods described in the 4,946,778, genetic sequences coding for the polypeptide can be obtained.

Preferably, the peptide linker joining the V_H and V_L domains to form a scFv and the peptide linker joining two or more scFvs to form a multivalent single chain antibody have substantially the same amino acid sequence.

It is also necessary that the linker peptides be attached to the antibody fragments such that the binding of the linker to the individual antibody fragments does not interfere with the binding capacity of the antigen recognition site.

30

A preferred linker is based on the helical linker designated 205C as disclosed in Pantoliano et al. *Biochem.*, <u>30</u>, 10117-10125 (1991) but with the first and last amino acids changed because of the codon dictated by the Xho I site at one end and the Hind III site at the other. The amino acid sequence (SEQ ID NO: 5) of the preferred linker is as follows:

The linker is generally 10 to 50 amino acid residues. Preferably, the linker is 10 to 30 amino acid residues. More preferably the linker is 12 to 30 amino acid residues. Most preferred is a linker of 15 to 25 amino acid residues.

Expression vehicles for production of the molecules of the invention include plasmids or other vectors. In general, such vectors contain replicon and control sequences which are derived from species compatible with a host cell. The vector ordinarily carries a replicon site, as well as specific genes which are capable of providing phenotypic selection in transformed cells. For example, E. coli is readily transformed using pBR322 [Bolivar et al., Gene, 2, 95- (1977), or Sambrook et al., Molecular Cloning, Cold Spring Harbor Press, New York, 2nd 10 Ed. (1989)].

5

20

25

35

Plasmids suitable for eukaryotic cells may also be used. S. cerevisiae, or common baker's yeast, is the most commonly used among eukaryotic microorganisms, although a number of other strains, such as Pichia pastoris, are available. Cultures of cells derived from multicellular organisms such as SP2/0 or Chinese Hamster Ovary (CHO), which are available from the ATCC, may also be used as hosts. Typical of vector plasmids suitable for mammalian cells are pSV2neo and pSV2gpt (ATCC); pSVL and pKSV-10 (Pharmacia), pBPV-1/pML2d (International Biotechnology, Inc.).

The use of prokaryotic and eukaryotic viral expression vectors to express the genes for polypeptides of the present invention is also contemplated.

It is preferred that the expression vectors and the inserts which code for the single chain multivalent antibodies have compatible restriction sites at the insertion junctions and that those restriction sites are unique to the areas of insertion. Both vector and insert are treated with restriction endonucleases and then ligated by any of a variety of methods such as those described in Sambrook et al., supra.

Preferred genetic constructions of vectors for production of single chain multivalent antibodies of the present invention are those which contain a constitutively active transcriptional promoter, a region encoding signal peptide which will direct synthesis/secretion of the nascent single chain polypeptide out of the cell. Preferably, the expression rate is commensurate with the transport, folding and assembly steps to avoid accumulation of the 30 polypeptide as insoluble material. In addition to the replicon and control sequences, additional elements may also be needed for optimal synthesis of single chain polypeptide. These elements may include splice signals, as well as transcription promoter, enhancers, and termination signals. Furthermore, additional genes and their products may be required to facilitate assembly and folding (chaperones).

Vectors which are commercially available can easily be altered to meet the above criteria for a vector. Such alterations are easily performed by those of ordinary skill in the art in light of the available literature and the teachings herein.

Additionally, it is preferred that the cloning vector contain a selectable marker, such as a drug resistance marker or other marker which causes expression of a selectable trait by the host cell. "Host cell" refers to cells which can be recombinantly transformed with vectors constructed using recombinant DNA techniques. A drug resistance or other selectable marker is intended in part to facilitate in the selection of transformants. Additionally, the presence of a selectable marker, such as a drug resistance marker, may be of use in keeping contaminating microorganisms from multiplying in the culture medium. In this embodiment, such a pure culture of the transformed host cell would be obtained by culturing the cells under conditions which require the induced phenotype for survival.

5

10

20

Recovery and purification of the present invention can be accomplished using standard techniques known in the art. For example, if they are secreted into the culture medium, the single chain multivalent antibodies can be concentrated by ultrafiltration. When the polypeptides are transported to the periplasmic space of a host cell, purification can be accomplished by osmotically shocking the cells, and proceeding with ultrafiltration, antigen affinity column chromatography or column chromatography using ion exchange chromatography and gel filtration. Polypeptides which are insoluble and present as refractile bodies, also called inclusion bodies, can be purified by lysis of the cells, repeated centrifugation and washing to isolate the inclusion bodies, solubilization, such as with guanidine-HCl, and refolding followed by purification of the biologically active molecules.

The activity of single chain multivalent antibodies can be measured by standard assays known in the art, for example competition assays, enzyme-linked immunosorbant assay (ELISA), and radioimmunoassay (RIA).

The multivalent single chain antibodies of the present invention provide unique benefits for use in diagnostics and therapeutics. The use of multivalent single chain antibodies afford a number of advantages over the use of larger fragments or entire antibody molecules. They reach their target tissue more rapidly, and are cleared more quickly from the body.

For diagnostic and/or therapeutic uses, the multivalent single chain antibodies can be constructed such that one or more antibody fragments are directed against a target tissue and one or more antibody fragments are directed against a diagnostic or therapeutic 30 agent.

The invention also concerns pharmaceutical compositions which are particularly advantageous for use in the diagnosis and/or therapy of diseases, such as cancer, where target antigens are often expressed on the surface of cells. For diagnostic and/or therapeutic uses, the multivalent single chain antibodies can be conjugated with an appropriate imaging or therapeutic agent by methods known in the art. The pharmaceutical compositions of the invention are prepared by methods known in the art, e.g., by conventional mixing, dissolving or lyophilizing processes.

The invention will be further clarified by a consideration of the following examples, which are intended to be purely exemplary of the present invention.

ABBREVIATIONS

	BCIP	5-bromo-4-chloro-3-indoyl phosphate
	bp	base pair
5	Bis-Tris propane	<pre>(1,3-bis[tris(hydroxymethyl)-methylamino]- propane)</pre>
	BSA	bovine serum albumin
	CDR	Complementarity determining region
	ELISA	enzyme linked immunosorbent assay
	Fv2	non-covalent single chain Fv dimer
10	IEF	isoelectric focusing
	Kbp	kilo base pair
	LB	Luria-Bertani medium
	Mab	monoclonal antibody
,	MES	2-(N-Morpholino)ethane sulfonic acid
15	MW	molecular weight
	NBT	nitro blue tetrazolium chloride
	Oligo	Oligonucleotides
	PAG	polyacrylamide gel
	PAGE	polyacrylamide gel electrophoresis
20	PBS	phosphate buffered saline
	PCR	polymerase chain reaction
	pSCFV	plasmid containing DNA sequence coding for SCFV
	RIGS	radioimmunoguided surgery
25	RIT	radioimmunotherapy
25	scFv	single chain Fv immunoglobulin fragment monomer
	scFv2	single chain Fv immunoglobulin fragment dimer covalently linked
	SDS	sodium dodecyl sulfate
	TBS	Tris-buffered saline
30	Tris	(Tris[hydroxymethy1]aminomethane)
	TTBS	Tween-20 wash solution
	VH	immunoglobulin heavy chain variable domain
	V <u>L</u>	immunoglobulin light chain variable domain

35

<u>Antibodies</u>

<u>CC49</u>: A murine monoclonal antibody specific to the human tumor-associated glycoprotein 72 (TAG-72) deposited as ATCC No. HB9459.

<u>CC49 FAB</u>: An antigen binding portion of CC49 consisting of an intact light chain linked to the N-terminal portion of the heavy chain.

<u>CC49 scFv</u>: Single chain antibody fragment consisting of two variable domains of CC49 antibody joined by a peptide linker.

CC49 Fv2: Two CC49 scFv non-covalently linked to form a dimer. The number after Fv refers to the number of monomer subunits of a given molecule, e.g., CC49 Fv6 refers to the hexamer multimers.

<u>CC49 scFv2</u>: Covalently-linked single chain antibody fragment consisting of two CC49 V_L domains and two V_H domains joined by three linkers. Six possible combinations for the order of linking the $V_L(L)$ and the $V_H(H)$ domains together are: LHLH, LHHL, LLHH, HLLH, and HHLL.

15 Plasmids

<u>pSCFV UHM</u>: Plasmid containing coding sequence for scFv consisting of a CC49 variable light chain and a CC49 variable heavy chain joined by a 25 amino acid linker.

<u>p49LHLH or p49LHHL</u>: Plasmids containing the coding sequence for producing CC49 scFv2 LHLH or LHHL products, respectively.

20 EXAMPLES

General Experimental

Procedures for molecular cloning are as those described in Sambrook et al.,

Molecular Cloning, Cold Spring Harbor Press, New York, 2nd Ed. (1989) and Ausubel et al.,

Current Protocols in Molecular Biology, John Wiley and Sons, New York (1992), the disclosures
of which are hereby incorporated by reference.

All water used throughout was deionized distilled water.

Oligonucleotide Synthesis and Purification

All oligonuclotides (oligos) were synthesized on either a Model 380A or a Model 391 DNA Synthesizer from Applied Biosystems (Foster City, CA) using standard β-cyanoethyl phosphoramidites and synthesis columns. Protecting groups on the product were removed by heating in concentrated ammonium hydroxide at 55°C for 6 to 15 hours. The ammonium hydroxide was removed through evaporation and the crude mixtures were resuspended in 30 to 40 μL of sterile water. After electrophoresis on polyacrylamide-urea gels, the oligos were visualized using short wavelength ultraviolet (UV) light. DNA bands were excised from the gel and eluted into 1 mL of 100 mM Tris-HCl, pH 7.4, 500 mM NaCl, 5 mM EDTA over 2 hours at 65°C. Final purification was achieved by applying the DNA to Sep-PacTM C-18 columns (Millipore, Bedford, MA) and eluting the bound oligos with 60 percent methanol. The

solution volume was reduced to approximately 50 μ L and the DNA concentration was determined by measuring the optical density at 260 nm (OD₂₆₀).

All restriction enzyme digests were performed using Bethesda Research
Laboratories (Gaithersburg, MD), New England Biolabs, Inc. (Beverly, MA) or Boehringer
Mannheim (BM, Indianapolis, IN) enzymes and buffers following the manufacturer's
recommended procedures. Digested products were separated by polyacrylamide gel
electrophoresis (PAGE). The gels were stained with ethidium bromide, the DNA bands were
visualized using long wavelength UV light and the DNA bands were then excised. The gel slices
were placed In dialysis tubing (Union Carbide Corp., Chicago) containing 5 mM Tris, 2.5 mM
acetic acid, 1 mM EDTA, pH 8.0 and eluted using a Max Submarine electrophoresis apparatus
(Hoefer Scientific Instruments, CA). Sample volumes were reduced on a Speed Vac
Concentrator (Savant Instruments, Inc., NY). The DNA was ethanol precipitated and redissolved
in sterile water.

15 Enzyme Linked Immunosorbent Assay (ELISA)

Restriction Enzyme Digests

TAG-72 antigen, prepared substantially as described by Johnson et al, Can. Res., 46, 850-857 (1986), was adsorbed onto the wells of a polyvinyl chloride 96 well microtiter plate (Dynatech Laboratories, Inc., Chantilly, VA) by drying overnight. The plate was blocked with 1 percent BSA in PBS for 1 hour at 31°C and then washed 3 times with 200 µL of PBS, 20 0.05 percent Tween-20. 25 μ L of test antibodies and 25 μ L of biotinylated CC49 (1/20,000 dilution of a 1 mg/mL solution) were added to the wells and the plate incubated for 30 minutes at 31°C. The relative amounts of TAG-72 bound to the plate, biotinylated CC49, streptavidinalkaline phosphatase, and color development times were determined empirically in order not to have excess of either antigen or biotinylated CC49, yet have enough signal to detect competition by scFv. Positive controls were CC49 at 5 μ g/mL and CC49 Fab at 10 μ g/mL. Negative controls were 1 percent BSA in PBS and/or concentrated LB. Unbound proteins were washed away. 50 µL of a 1:1000 dilution of streptavidin conjugated with alkaline phosphatase (Southern Biotechnology Associates, Inc., Birmingham, AL) were added and the plate was incubated for 30 minutes at 31°C. The plate was washed 3 more times. 50 µL of a para-nitrophenyl-phosphate solution (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD) were added and the color reaction was allowed to develop for a minimum of 20 minutes. The relative amount of scFv2 binding was measured by optical density scanning at 404-450 nm using a microplate reader (Molecular Devices Corporation, Manlo Park, CA). Binding of the scFv2 species resulted in decreased binding of the biotinylated CC49 with a concomitant 35 decrease in color development.

SDS-PAGE and Western Blotting

Samples for SDS-PAGE analysis (20 μ L) were prepared by boiling in a non-reducing sample preparation buffer-Seprasol I (Integrated Separation Systems (ISS), Natick, MA) for

5 minutes and loaded on 10-20 percent gradient polyacrylamide Daiichi Minigels as per the manufacturer's directions (ISS).

Electrophoresis was conducted using a Mini 2-gel apparatus (ISS) at 55 mA per gel at constant current for approximately 75 minutes. Gels were stained in Coomassie Brilliant Blue R-250 (Bio-Rad, Richmond, CA) for at least 1 hour and destained. Molecular weight standards were prestained (Mid Range Kit, Diversified Biotech, Newton Center, MA) and included the following proteins: Phosphorylase b, glutamate dehydrogenase, ovalbumin, lactate dehydrogenase, carbonic amhydrase, B-lactoglobulin and cytochrome C. The corresponding MWs are: 95,500, 55,000, 43,000, 36,000, 29,000, 18,400, and 12,400, respectively.

10

When Western analyses were conducted, a duplicate gel was also run. After electrophoresis, one of the gels was equilibrated for 15-20 minutes in anode buffer #1 (0.3 M Tris-HCl pH 10.4). An Immobilon-P PVDF (polyvinylidene dichlorine) membrane (Millipore, Bedford, MA) was treated with methanol for 2 seconds, and immersed in water for 2 minutes. The membrane was then equilibrated in anode buffer #1 for 3 minutes. A Milliblot-SDE apparatus (Millipore) was utilized to transfer proteins in the gel to the membrane. A drop of anode buffer #1 was placed in the middle of the anode electrode surface. A sheet of Whatman 3MM filter paper was soaked in anode buffer #1 and smoothly placed on the electrode surface. Another filter paper soaked in anode buffer #2 (25 mM tris pH 10.4) was placed on top of the first one. A sandwich was made by next adding the wetted PVDF membrane, placing the 20 equilibrated gel on top of this and finally adding a sheet of filter paper soaked in cathode buffer (25mM Tris-HCl, pH 9.4 in 40 mM glycine). Transfer was accomplished in 30 minutes using 250 mA constant current (initial voltage ranged from 8-20 volts).

After blotting, the membrane was rinsed briefly in water and placed in a dish with 20 mL blocking solution (1 percent bovine serum albumin (BSA) (Sigma, St. Louis, MO) in 25 Tris-buffered saline (TBS)). TBS was purchased from Pierce Chemical (Rockford, IL) as a preweighed powder such that when 500 mL water is added, the mixture gives a 25 mM Tris, 0.15 M sodium chloride solution at pH 7.6. The membranes were blocked for a minimum of 1 hour at ambient temperature and then washed 3 times for 5 minutes each using 20 mL 0.5 percent Tween-20 wash solution (TTBS). To prepare the TTBS, 0.5mL of Tween 20 (Sigma) 30 was mixed per liter of TBS. The probe antibody used was 20 mL biotinylated FAID14 solution (10 µg per 20 mL antibody buffer). Antibody buffer was made by adding 1 g BSA per 100 mL of TTBS. After probing for 30-60 minutes at ambient temperature, the membrane was washed 3 times with TTBS, as above.

Next, the membrane was incubated for 30-60 minutes at ambient temperature with 20 mL of a 1:500 dilution in antibody buffer of streptavidin conjugated with alkaline phosphatase (Southern Biotechnology Associates, Birmingham, AL). The wash step was again repeated after this, as above. Prior to the color reaction, membranes were washed for 2 minutes in an alkaline carbonate buffer (20 mL). This buffer is 0.1 M sodium bicarbonate,

PCT/US93/12039 WO 94/13806

1 mM MgCl₂·H₃0, pH 9.8. To make up the substrate for alkaline phosphatase, nitroblue tetrazolium (NBT) chloride (50 mg, Sigma) was dissolved in 70 percent dimethylformamide. 5-Bromo-4-chloro-3-indoyl phosphate (BCIP) (25 mg, Sigma) was separately dissolved in 100 percent dimethylformamide. 5-Bromo-4-chloro-3-indoyl phosphate (BCIP) 25 mg, Sigma) was separately dissolved in 100 percent dimethylformamide. These solutions are also commercially available as a Western developing agent sold by Promega. For color development, 120 µL of each were added to the alkaline solution above and allowed to react for 15 minutes before they were washed from the developed membranes with water. **Biotinylated FAID14**

10

Isoelectric Focusing (IEF)

FAID14 is a murine anti-idiotypic antibody (IgG2a, K isotype) deposited as ATCC No. CRL 10256 directed against CC49. FAID14 was purified using a Nygene Protein A affinity column (Yonkers, NY). The manufacturer's protocol was followed, except that 0.1 M sodium citrate, pH 3.0 was used as the elution buffer. Fractions were neutralized to pH \sim 7 using 1.0 M Tris-HCl pH 9.0. The biotinylation reaction was set up as follows. FAID14 (1 mg, 100 μL in water) was mixed with 100 μ L of 0.1 M Na₂CO₃ pH 9.6. Biotinyl- ϵ -amino-caproic acid N-hydroxy succinimide ester (Biotin-X-NHS) (Calbiochem, LaJolla, CA) (2.5 mg) was dissolved in 0.5 mL dimethylsulfoxide. Biotin-X-NHS solution (20 µL) was added to the FAID14 solution and allowed to react at 22°C for 4 hours. Excess biotin and impurities were removed by gel filtration, using a Pharmacia Superose 12 HR10/30 column (Piscataway, NJ). At a flow rate of 0.8 mL/min, the biotinylated FAID14 emerged with a peak at 16.8 min. The fractions making up this peak were pooled and stored at 4°C and used to detect the CC49 idiotype as determined by the CC49 V₁ and V₂ CDRs.

Isoelectric points (pl's) were predicted using a computer program called PROTEIN--TITRATE, available through DNASTAR (Madison, WI). Based on amino acid composition with an input sequence, a MW value is given, in addition to the pl. Since Cys residues contribute to the charge, the count was adjusted to 0 for Cys, since they are all involved in disulfide bonds.

Experimentally, pl's were determined using Isogel agarose IEF plates, pH range 3-10 (FMC Bioproducts, Rockland, ME). A Biorad Bio-phoresis horizontal electrophoresis cell 30 was used to run the IEF, following the directions of both manufacturers. The electrophoresis conditions were: 500 volts (limiting), at 20 mA current and 10 W of constant power. Focusing was complete in 90 min. IEF standards were purchased from Biorad; the kit included phycocyanin, β-lactoglobulin B, bovine carbonic anhydrase, human carbonic anhydrase, equine myoglobin, human hemoglobins A and C, 3 lentil lectins and cytochrome C, with pl values of 35 4.65, 5.10, 6.00, 6.50, 7.00, 7.10 and 7.50, 7.80, 8.00, and 8.20 and 9.60, respectively. Gels were stained and destained according to the directions provided by FMC.

Quantitation of CC49 Antibody Species

All purified CC49 antibodies including the IgG, scFv2 species and the monomeric scFv were quantitated by measuring the absorbence of protein dilutions at 280 mm using matching 1.0 cm pathlength quartz cuvettes (Hellma) and a Perkin-Elmer UV/VIS Spectrophotometer, Model 552A. Molar absorptivities (E_m) were determined for each antibody by using the following formula:

 $E_{m} = (number Trp) X 5,500 + (number Tyr) X 1,340 + (number (Cys)2) X 150 + (number Phe) X 10$

The values are based on information given by D. B. Wetlaufer, *Advances in Protein Chemistry*, 10 17, 375-378).

High Performance Liquid Chromatography

All high performance liquid chromatography (HPLC) was performed for CC49 scFv2 purification using an LKB HPLC system with titanium or teflon tubing throughout. The system consists of the Model 2150 HPLC pump, model 2152 controller, UV CORD SII model 2238 detection system set at an absorbence of 276 nm and the model 2211 SuperRac fraction collector.

PCR Generation of Subunits

All polymerase chain reactions (PCR) were performed with a reaction mixture consisting of: 150 picograms (pg) plasmid target (pSCFVUHM); 100 pmoles primers; 1 μL

Perkin-Elmer-Cetus (PEC, Norwalk, CT) Ampli-Taq polymerase; 16 μL of 10 mM dNTPs and 10 μL of 10X buffer both supplied in the PEC kit; and sufficient water to bring the volume to total volume to 100 μL. The PCR reactions were carried out essentially as described by the manufacturer. Reactions were done in a PEC 9600 thermocycler with 30 cycles of: denaturation of the DNA at 94°C for 20 to 45 sec, annealing from between 52 to 60°C for 0.5 to 1.5 min., and elongation at 72°C for 0.5 to 2.0 min. Oligonucleotide primers were synthesized on an Applied Biosystems (Foster City, CA) 380A or 391 DNA synthesizer and purified as above.

Ligations

Ligation reactions using 100 ng of vector DNA and a corresponding 1:1 stoichiometric equivalent of insert DNA were performed using a Stratagene (La Jolla, CA) T4

DNA ligase kit following the manufacturer's directions. Ligation reactions (20 µL total volume) were initially incubated at 18°C and allowed to cool gradually overnight to 4°C.

<u>Transformations</u>

Transformations were performed utilizing 100 µL of Stratagene E. coli AG1 competent cells (Stratagene, La Jolla, CA) according to the directions provided by the manufacturer. DNA from the ligation reactions (1-5 µL) were used. After the transformation step, cells were allowed to recover for 1 hr in Luria broth (LB) at 37°C with continuous mixing and subsequently plated onto either 20 µg/mL chloramphenicol containing (CAM 20) Luria agar for pSCFVUHM, p49LHLH or p49LHHL or 100 µg/mL ampicillin (AMP 100) Luria agar plates

(LB-AMP 100) for clones containing the plasmid pSL301 or subsequent constructions derived from pSL301.

Screening of E. coli Clones

Bacterial plasmids were isolated from LB broth culture containing the appropriate drug to maintain selection pressure using Promega (Madison, WI) Magic mini-prep plasmid preparation kits. The kit was used per the manufacturer's specifications.

Plasmid Constructions

5

15

Two plasmids, designated p49LHLH and p49LHHL, were constructed to produce multivalent single chain antibodies. The host cell containing p49LHLH produced a polypeptide which can be designated by V_L -L- V_H -L- V_L -L- V_H where V_L and V_H are the light and heavy cahin variable regions of CC49 antibody and linker (L) is a 25 amino acid linker having the sequence (SEQ ID NO: 5).

Leu-Ser-Ala-Asp-Asp-Ala-Lys-Lys-Asp-Ala-Lys-Lys-Asp-Ala-Lys-Lys-Asp-Asp-Ala-Lys-Lys-Asp-Asp-Ala-Lys-Lys-Asp-Leu.

The host cell containing p49LHHL produced a polypeptide which can be designated by V_L -L- V_H -L- V_H -L- V_L where V_L and V_H are the light and heavy chain variable domains of the CC49 antibody and L is a peptide linker having the amino acid sequence indicated above.

The nucleotide sequence (SEQ ID NO: 6) and amino acid sequence (SEQ ID NO: 7)

20 of the CC49 V_L-L-V_H-L-V_L-L-V_H (p49LHLH) are given in Figure 6. The nucleotide sequence (SEQ ID NO: 8) and amino acid sequence (SEQ ID NO: 9) of the CC49 V_L-L-V_H-L-V_H-L-V_L (p49LHHL) are given in Figure 7.

Construction of pSL301 HT

The construction of pSL301 HT is illustrated in Figure 8. The Bacillus lichiformis penicillinase P (penP) terminator sequence was removed from the plasmid designated pSCFV UHM by a 45 minute digest with Nhe I and BamH I, excised from a 4.5 percent polyacrylamide gel after electrophoresis, electroeluted, ethanol precipitated and ligated into the same sites in the similarly prepared vector: pSL301 (Invitrogen, San Diego, CA). A procedure for preparing pSCFV UHM is given is U.S. patent application Ser. No. 07/935,695 filed August 21, 1992, the disclosure of which is hereby incorporated by reference. In general, pSCFV UHM contains a nucleotide sequence for a penP promoter; a unique Nco I restriction site; CC49 V_L region; Hind III restriction site; a 25 amino acid linker; a unique a Xho I restriction site; CC49 V_H region; Nhe I restriction site; penP terminator; and BamH I restriction site (see, Figure 8). The penP promoter and terminator are described in Mezes, et al. (1983), J. Biol.

An aliquot of the ligation reaction (3 μ L) was used to transform competent *E. coli* AG1 cells which were plated on LB-AMP100 agar plates and grown overnight. Potential clones containing the penP terminator insert were screened using a Pharmacia (Gaithersburg, MD) T7

Quickprime 32P DNA labeling kit in conjunction with the microwave colony lysis procedure outlined in Buluwela et al., Nucleic Acid Research, 17, 452 (1989). The probe, which was the penP-Nhe I-BamH I terminator fragment itself was prepared and used according to the directions supplied with the Quickprime kit. A clone which was probe positive and which contained the 207 base pair inserts from a BamH I and Nhe I digest (base pairs (bp) 1958 to 2165, Figure 6) was designated pSL301 T and chosen to construct pSL301 HT which would contain the nucleotide sequence for CC49 V_H. The reason the Nhe I-BamH I penP terminator was placed into pSL301 was to eliminate the Eco47 III restriction endonuclease site present in the polylinker region between its Nhe I and BamH I sites. This was designed to accommodate the subsequent build-up of the V_L and V_H domains where the Eco47 III site needed to be unique for the placement of each successive V domain into the construction. As each V domain was added at the Eco47 III-Nhe I sites, the Eco47 III was destroyed in each case to make the next Eco47 III site coming in on the unique insert.

The V_H sequence was made by PCR with oligos 5' SCP1 and 3'oligo SCP5 using pSCFV UHM as the target for PCR amplification. The DNA sequence for SCP1 (SEQ ID NO: 10) and SCP5 (SEQ ID NO: 11) are as follows:

SCP1: 5'-TAAA CTC GAG GTT CAG TTG CAG CAG -3'

20

35

SCP5: 5'-TAAA GCT AGC ACCA AGC GCT TAG TGA GGA GAC GGT GAC TGA GGT-3' The underlined portion indicates the endonuclease restriction sites.

The amplified V_H DNA was purified from a 4 percent PAG, electroeluted ethanol precipitated and dissolved in 20 μ L water. The V_H sequence was digested with Xho I and Nhe I restriction enzymes and used as the insert with the pSL301 T vector which had been digested with the same restriction enzymes and subsequently purified. A standard ligation reaction was done and an aliquot (4 µL) used to transform competent E. coli AG1 cells. The transformed cells 25 were plated onto LB AMP100 agar plates. Candidate clones were picked from a Nhe I and Xho I digest screen that revealed that the CC49V_H insert had been obtained.

DNA sequencing was performed to verify the sequence of the CC49V_H with United States Biochemical (USB) (Cleveland, Ohio) Sequence kit and sequencing primers pSL301SEQB (a 21 bp sequencing primer which annealed in the pSL301 vector 57 bp upstream 30 from the Xho I site) and CC49VHP, revealed clones with the correct CC49V_H sequence in pSL301HT. This plasmid was used as the starting point in the construction of both pSL301-HHLT and pSL301-HLHT. The sequencing oligos used are shown here.

The nucleotide sequence of pSL301SEQ B (SEQ ID NO: 12) and CC49V_H (SEQ ID No: 13) are as follows:

> pSL301SEQB: 5'-TCG TCC GAT TAG GCA AGC TTA-3' CC49VHP: 5'-GAT GAT TTT AAA TAC AAT GAG-3'

PCT/US93/12039 WO 94/13806

Example 1 p49LHHL Construction

20

30

Using pSL301 HT (5 µg) as the starting material, it was digested with Eco47 III and Nhe I and the larger vector fragment was purified. A CC49V_H insert fragment was generated by PCR using SCP6C as the 5' oligo and SCP5 as the 3' oligo. The nucleotide sequence (SEQ ID NO: 14) of SCP6B is as follows:

SCP6B: 5'- TAAA <u>TGC GCA</u> GAT GAC GCA AAG AAA GAC GCA GCT AAA AAA GAC GAT GCC AAA AAG GAT GAC GCC AAG AAA GAT CTT GAG GTT CAG TTG CAG CAG TCT-G'

The oligo SCP6B also contains part of the coding region for the linker (bp 8-76 of SEQ ID NO: 14). The portion of the oligo designed to anneal with the CC49VH target in pSCFV UHM is from bp77-90 in SEQ ID NO: 14.

The underlined sequence corresponds to the Fsp I site. The resulting PCR insert was purified, digested with Fsp I and Nhe I and used in a ligation reaction with the pSL301 HT Eco47 III-Nhe I vector (Figure 7). Competent E. coli AG1 cells were used for the transformation of this ligation reaction (3 μ L) and were plated on LB-AMP100 agar plates. Two clones having the correct size Xho I-Nhe I insert representative of the pSL301 HHT product were sequenced with the oligo SQP1 and a single clone with the correct sequence (nucleotides 1124-1543 of Figure 7) was chosen for further construction. The nucleotide sequence of SQP1 (SEQ ID NO: 16) is as follows:

SOP1: 5'-TG ACT TTA TGT AAG ATG ATG T-3'

The final linker- V_1 subunit (bp 1544-1963, Figure 7) was generated using the 5'oligo, SCP7b and the 3' oligo, SCP8a, using pSCFV UHM as the target for the PCR. The nucleotide sequence of SCP7b (SEQ ID NO: 17 is as follows:

SCP7b: 5'-TAAA TGC GCA GAT GAC GCA AAG AAA GAC GCA GCT AAA AAA GAC GAT GCC AAA AAG GAT GAC GCC AAG AAA GAT CTT GAC ATT GTG ATG TCA CAG TCT 25 CC

The underlined nucleotides correspond to an Fsp I site. The nucleotide sequence of SCP8a (SEQ ID NO: 18) is as follows:

> 5'-TAAA GCT AGC TTT TTA CTT AAG CAC CAG CTT GGT CCC-3' SCP8a:

The first set of underlined nucleotides correspond to an Nhe I site, while the other corresponds to an AfI II site. Nucleotides 8-76 of SCP70 code for the linker (nucleotides 1544-1612 of Figure 7) while nucleotides 77-99 which anneal to the V_L correspond to 1613-1635 of Figure 7. The primer SCP8a has a short tail at its 5' end, a Nhe I restriction site, a stop codon, an AfI II restriction site and the last 21 bases of the V_L . After Fsp I and Nhe I digestion, this resulting 420 bp insert was purified and ligated into the Nhe I and Eco47 III sites of the purified pSL301HHT vector, candidate clones were screened with Nhe I and Xho I, the correct size insert verified and sequenced with 49LFR2(-) and SQP1 to confirm the newly inserted sequence in pSL301HHLT. The nucleotide sequence (SEQ ID NO: 19) is as follows:

49LFR2(-): 5'-CTG CTG GTA CCA GGC CAA G-3'

The plasmid pSL301HHLT was digested with Xho I and Nhe I, purified, and the resulting 1179 bp V_H -linker- V_H -linker- V_L segment ligated into pSCFV UHM, which had been cut with the same restriction enzymes and the larger vector fragment purified, to form p49LHHL. The ligation reaction (4 μ L aliquot) was used to transform competent E. coli AG1 cells (Stratagene) and plated onto LBCAM20 agar plates. A single clone which had a plasmid with the correct restriction enzyme map was selected to contain p49LHHL. The p49LHHL contains a penP promoter and a nucleotide sequence for the CC49 multivalent single chain antibody scFv2:

 V_L -L- V_H -L- V_H -L- V_L or CC49 scFv2 (LHHL).

Example 2: p49LHLH Construction

10

15

The construction of p49LHLH is schematically represented in Figure 11. A linker- V_L subunit was generated with the 5' oligo SCP7b and the 3'oligo SCP9.

SCP9: 5'-TAA AGC TAG CAC CAA GCG CTT AGT TTC AGC ACC AGC TTG GTC CCA G-3'
The SCP7b oligo (nucleotides 8-76) codes for the linker in Figure 6 (corresponding to nucleotides 1124-1192) and annealed to the pSCFV UHM target for the PCR (nucleotides

77-99) corresponding to nucleotides 1193-1215 of the V_i in Figure 6.

underlined nucleotides) which are restriction sites needed for making the pSL301HLT ready to accept the next V domain. Nucleotides 18-23 of SCP9 correspond to nucleotides 1532-1537 of Figure 6 (coding for the first 2 amino acids of the linker), while nucleotides 24-46 correspond to nucleotides 1508-1531 of Figure 6 which was also the annealing region for SCP9 in the PCR. The plasmid pSL301 HT was digested with Eco47 III and Nhe I and the larger vector fragment was purified for ligation with the linker-CC49V_L DNA insert fragment from the PCR which had been treated with Fsp I and Nhe I and purified. The ligation mixture (3 µL) was used to transform *E. coli* AG1 competent cells and one colony having the correct Xho I-Nhe I size fragment was sequenced using the oligo PENPTSEQ2. The nucleotide sequence (SEQ. ID NO. 21) is as follows:

5'-TTG ATC ACC AAG TGA CTT TAT G-3'

The sequencing results indicated that there had been a PCR error and deletion in the resulting pSL301HT clone. A five base deletion, corresponding to nucleotides 1533-1537 as seen in Figure 6 had been obtained and nucleotide 1531 which should have been a T was actually a G, as determined from the DNA sequence data. The resulting sequence was

5'...G AAGC GCT T...etc.

where the underlined sequence fortuitously formed an Eco47 III site. The

35 AGCGCT sequence in Figure 6, would correspond to nucleotides 1530, 1531, 1532, 1538, 1539

and 1540. This error was corrected in the next step, generating pSL301 HLHT, by incorporating the 5 base deletion at the end of oligo SCP6C.

PCT/US93/12039 WO 94/13806

SCP6C: 5'-TAAGCGCTGATGATGCTAAGAAGGACGCCGCAAAAAA **GGACGACGCAAAAAAAGATGATGCAAAAAAGGATCTGG** AGGTTCAGTTGCAGCAGTCTGAC-3'

The underlined sequence in SCP6c corresponds to an Eco47 III site. SCP6C was used as the 5' oligo, with SCP10 as the 3' oligo in a PCR to generate a linker CC49 V, segment. The nucleotide sequence (SEQ ID NO: 23) is as follows:

SCP10: 5'TTG TGC TAG CTT TTT ATG AGG AGA CGG TGA CTG AGG TT-3'

The underlined sequence in SCP10 corresponds to the Nhe I site found at nucleotides 1958-1963 in Figure 6. The PCR insert was digested this time only with Nhe I and purified. The vector (pSL301 HLT) was digested at the Eco47 III site (that had been formed) and Nhe I and purified. The insert and vector were ligated and an aliquot (3 µL) used to transform competent E. coli AG1 cells. This was plated on LB-AMP100 plates and candidate clones screened with Xho I and Nhe I. Three clones having the correct size DNA were obtained. Two of these clones were sequenced using the oligo 49VLCDR3(+) and SQP1. The nucleotide 15 sequence (DWQ ID NO: 24 of 49VLCDR3(+) is as follows:

49VLCDR3(+):

20

5'-CAG CAG TAT TAT AGC TAT-3'

One clone, with the correct sequence was obtained and the sequence from nucleotides 1533 to 1963 in Figure 6 were verified, giving a correct pSL301 HLHL clone.

To generate the final plasmid, p49LHLH for expression in E. coli, pSL301 HLHT (5 µg) was digested with Nhe I and Xho I, and the smaller insert fragment containing the V_H-L-V_L-L-V_H sequence purified. It was ligated with the larger purified vector fragment from a digest of pSCFV UHM (5 μ g) with Xho I and Nhe I. An aliquot of the ligation mix (4 μ L) was used to transform competent E. coli AG1 cells. The transformation mix was plated on LB-CAM20 25 plates, and a representative clone for p49 LHLH was selected on the basis of a correct restriction enzyme map (see Figure 10) and biological activity toward TAG-72.

Example 3: Purification of CC49 scFv2 LHLH and LHHL Covalently Linked Dimers For the purification of the CC49 covalently linked single chain dimers, (scFv2), E. coli periplasmic fractions were prepared from 1.0 L overnight cultures of both p49LHLH and 30 p49LHHL. Briefly, the culture was divided into 4 X 250 mL portions and centrifuged at 5,000 rpm for 10 minutes in a Sorvall GS-3 rotor. The pelleted cells were washed and resuspended in 100 mL each of 10 mM Tris-HCl pH 7.3 containing 30 mM NaCl. The cells were again pelleted and washed with a total of 100 mL 30 mM Tris-HCl pH 7.3 and pooled into one tube. To this, 100 mL of 30 mM Tris-HCl pH 7.3 containing 40 percent w/v sucrose and 2.0 mL of 35 10 mM EDTA pH 7.5 was added. The mixture was kept at room temperature, with occasional shaking, for 10 minutes. The hypertonic cells were then pelleted as before. In the next step, the shock, the pellet was quickly suspended in 20 mL ice cold 0.5 mM MgCl₂ and kept on ice for 10 minutes, with occasional shaking. The cells were pelleted as before and the supernatant

PCT/US93/12039 WO 94/13806

containing the E. coli periplasmic fraction was clarified further by filtration through a 0.2 µm Nalge (Rochester, NY) filter apparatus and concentrated in Amicon (Danvers, MA) Centriprep 30 and Centricon 30 devices to a volume of less than 1.0 mL.

5

The concentrated periplasmic shockates from either the p49LHLH or p49LHHL clones were injected onto a Pharmacia (Piscataway, NJ) Superdex 75 HR 10/30 HPLC column that had been equilibrated with PBS. At a flow rate of 0.5 mL/minute, the product of interest, as determined by competition ELISA, had emerged between 21 through 24 minutes. The active fractions were pooled, concentrated as before and dialyzed overnight using a system 500 Microdialyzer Unit (Pierce Chemical) against 20 mM Tris-HCl pH 7.6 with 3-4 changes of buffer and using an 8,000 MW cut-off membrane. The sample was injected on a Pharmacia Mono Q HR 5/5 anion exchange HPLC column. A gradient program using 20 mM Tris-HCl pH 7.6 as buffer A and the same solution plus 0.5 M NaCl as buffer B was employed at a flow rate of 1.5 mL/min. The products of interest in each case, as determined by competition ELISA, emerged from the column between 3 and 4 minutes. Analysis of the fractions at this point on 15 duplicate SDS-PAGE gels, one stained with Coomassie Brilliant Blue R-250 and the other transferred for Western analysis (using biotinylated FAID 14 as the probe antibody) revealed a single band at the calculated molecular weight for the scFv2 (LHLH or LHHL) species at 58,239 daltons. The active fractions were in each case concentrated, dialysed against 50 mM MES pH 5.8 overnight and injected on a Pharmacia Mono S HR 5/5 cation exchange column. The two 20 fractions of interest from this purification step, as determined by SDS-PAGE and ELISA, fractions .5 and 6, eluted just before the start of the gradient, so they had not actually bound to the column. Fractions 5 and 6 were consequently pooled for future purification.

A Mono Q column was again run on the active Mono S fractions but the buffer used was 20 mM Tris-HCl, pH 8.0 and the flow rate was decreased to 0.8 mL/minute. The 25 products emerged without binding, but the impurity left over from the Mono S was slightly more held up, so that separation did occur between 5 and 6 minutes. After this run, the products were homogeneous and were saved for further characterization. Isoelectric Focusing

The isoelectric points (pl) of the constructs was predicted using the DNASTAR (Madison, WI) computer program Protein-titrate. Based on amino acid composition, a MW and pi value was calculated.

Experimentally, pls were determined using FMC Bioproducts (Rockland, ME) Isogel IEF plates, pH range 3-10. A Biorad (Richmond, CA) electrophoresis unit was used to run the IEF, following the directions of both manufacturers. The electrophoresis conditions were as follows: 500 V (limiting) at 20 mA and at 10 W of constant power. Focusing was complete in 90 minutes. Biorad IEF standards included phycocyanin, beta lactoglobulin B, bovine carbonic anhydrase, human carbonic anhydrase, equine myoglobulin, human hemoglobins A and C, 3 lentil lectin, and cytochrome C with pl value of 4.65, 5.10, 6.00, 6,50, 7.00, 7.50, 7.8, 8.00, 8.20

WO 94/13806 PCT/US93/12039

and 9.6, respectively. Gels were stained and destained according to directions provided by FMC. The DNASTAR program predicted values of 8.1 for the pl for both scFv2 species. A single, homogeneous band for the pure products was observed on the gel at pl values for both at 6.9.

Purified CC49 antibodies such as the IgG, scFv2 (LHLH and LHHL) were quantitated by measuring the absorbence spectrophotometrically at 280 nm. Molar absorbtivity values, $\epsilon_{\rm M}$, were determined for each using the formula cited above by Wetlaufer.

Based on the amino acid composition, the E^{0.1%} (280 nanometers) values for CC49 IgG, CC49 scFv2 LHLH, CC49 scFv2 LHHL and CC49 scFv were 1.49, 1.65, 1.65 and 1.71, respectively.

10 Example 4

15

35

Relative activities of the CC49 scFv2 species LHLH and LHHL, were compared with the IgG and a monomer scFv form with a FLAG peptide at the COOH terminus.

Percent competition was determined from the ELISA data by the following equation:

Zero competition - sample reading (OD405-450 nm) x 100 zero competition - 100 percent competition

The "zero competition" value was determined by mixing (1:1) one percent BSA with the biotinylated CC49 (3 X 10-14 moles) while the 100 percent competition value was based on a 5 μ g/mL sample of CC49 IgG mixed with the biotinylated CC49 IgG. The data are presented in Figure 11. Absorbence values for the samples were measured at 405 nm - 450 nm.

The average of triplicate readings was used. Initially samples (25 μL) were applied to the TAG-72 coated microliter plates at 1.0 X 10-10 moles of binding sites/mL. Biotinylated CC49 (4 μg/μL diluted 1:20,000 - used 25 μL) diluted the samples by a factor of 2. Serial dilutions (1:2) were performed. Both forms of the scFv2 are approximately equivalent to the lgG (see Figure 11). In a separate experiment, a CC49 scFv monomer was compared to a Fab fragment, both of which are monovalent and these were also shown to be equivalent in their binding

affinity for TAG-72. These results indicate that both forms of the covalently linked dimers have 2 fully functional antigen binding sites. This is the same increase in avidity as observed with the whole IgG, relative to a monomeric species.

These data also indicate that the scFv2 molecules, like their CC49 IgG parent are candidates for immunotherapeutic applications, but with the benefit of increased capillary permeability and more rapid biodistribution pharmacokinetics. The advantage should allow multiple injections of compounds of the present invention and give higher tumor:tissue ratios in immunotherapeutic treatment regimens for cancer treatment, relative to the existing IgG molecules.

Other embodiments of the invention will be apparent to those skilled in the art from a consideration of this specification or practice of the invention disclosed herein. It is

WO 94/13806 PCT/US93/12039

intended that the specification and examples be considered as exemplary only, with the true scope and spirit of the invention being indicated by the following claims.

WO 94/13806 PCT/US93/12039

1. A mutivalent single chain antibody which comprises two or more single chain antibody fragments each fragment having affinity for an antigen wherein the fragments are covalently linked by a first peptide linker and each fragment comprising:

- (a) a first polypeptide comprising a light chain variable domain;
- (b) a second polypeptide comprising a heavy chain variable domain; and
- (c) a second peptide linker linking the first and second polypeptides into a functional binding moiety.
- 2. The multivalent single chain antibody of Claim 1 wherein the first peptide linker has the amino and sequence

Leu Ser Ala Asp Asp Ala Lys Lys Asp Ala Ala Lys Lys Asp Asp Ala Lys Lys Asp Asp Asp Ala Lys Lys Asp Leu.

- 3. The multivalent single chain antibody of Claim 1 wherein the light chain variable region has an amino acid sequence substantially the same as that of Figure 3 and the heavy chain variable region has an amino acid sequence substantially the same as that of Figure 5.
 - 4. The multivalent single chain antibody of Claim 1 wherein the first and second peptide linkers have an amino acid sequence which is substantially the same.
- 5. A DNA sequence which codes for a mutivalent single chain antibody, the multivalent single antibody comprising two or more single chain antibody fragments, each
 fragment having affinity for an antigen wherein the fragments are covalently linked by a first peptide linker and each fragment comprising:
 - (a) a first polypeptide comprising a light chain variable domain;
 - (b) a second polypeptide comprising a heavy chain variable domain; and
 - (c) a second peptide linker linking the first and second polypeptides into a functional binding moiety.
 - 6. The DNA sequence of Claim 5 wherein the sequence coding for the first polypeptide is substantially the same as that of Figure 2 and the sequence coding for the second polypeptide is substantially the same as that of Figure 3.


30

25

5

10

35



1/20

SUBSTITUTE SHEET (RULE 26)

FIG. 2

GAC ATT GTG ATG TCA CAG TCT CCA TCC TCC CTA CCT GTG TCA
GTT GGC GAG AAG GTT ACT TTG AGC TGC AAG TCC AGT CAG AGC
CTT TTA TAT AGT GGT AAT CAA AAG AAC TAC TTG GCC TGG TAC
CAG CAG AAA CCA GGG CAG TCT CCT AAA CTG CTG ATT TAC TGG
GCA TCC GCT AGG GAA TCT GGG GTC CCT GAT CGC TTC ACA GGC
AGT GGA TCT GGG ACA GAT TTC ACT CTC TCC ATC AGC AGT GTG
AAG ACT GAA GAC CTG GCA GTT TAT TAC TGT CAG CAG TAT TAT
AGC TAT CCC CTC ACG TTC GGT GCT GGG ACC AAG CTG GTG CTG
AAG

FIG. 3

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Pro Val Ser Val Gly Glu Lys Val Thr Leu Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ala Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Ser Ser Val Lys Thr Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Val Leu Lys

FIG. 4

GAG GTT CAG TTG CAG CAG TCT GAC GCT GAG TTG GTG AAA CCT
GGG GCT TCA GTG AAG ATT TCC TGC AAG GCT TCT GGC TAC ACC
TTC ACT GAC CAT GCA ATT CAC TGG GTG AAA CAG AAC CCT GAA
CAG GGC CTG GAA TGG ATT GGA TAT TTT TCT CCC GGA AAT GAT
GAT TTT AAA TAC AAT GAG AGG TTC AAG GGC AAG GCC ACA CTG
ACT GCA GAC AAA TCC TCC AGC ACT GCC TAC GTG CAG CTC AAC
AGC CTG ACA TCT GAG GAT TCT GCA GTG TAT TTC TGT ACA AGA
TCC CTG AAT ATG GCC TAC TGG GGT CAA GGA ACC TCA GTC ACC
GTC TCC TCA

FIG. 5

Glu Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His Ala Ile His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile Gly Tyr Phe Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Val Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Thr Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser

F1G. 6A

DNA AND AMINO ACID SEQUENCE OF CC49 VL-L-VH-L-VL-L-VH

917	π 6	142	190	238	286	334	382	0£#	81th
100	AAA	ATT	TTA	AGA	ACG		Pro	Lys AAG	40 A18 GCC
ည္သ	GAA	TAC	CAA	GAA	GAG		Ser	Cys 1GC	116 116
CTT	TCC	GAC	TAC	GTG	AGG	Leu	Gln	Ser	Tyr
TCA	CCT	AAA	ACG	ATA ATA	0 0 0 0 0	Gly	Ser	Leu TTG	Asn
CCA	TTT	TTC	CGT	999	AAA	Ala	Met ATG	20 Thr ACT	Lys
TGA ATT	TCA	ACT	GAT	GTA	TTC	Ala	Val GTG	Val	Gln
TGA	TCA	AAT	AAA	ACT	ATA	Ala	Ile ATT	Lys	Asn
CAT CGA	AGG	TAT	CTG	AAC	AAT CAA PENPR2-	Thr	VL Asp Gac	G1u GAG	61y 66T
CAT	ACG	ATA	990	CAT	AAT	Pro CC1	Ala GCC	G1y GGC	Ser
TAT	GAA	TAC	AGT (PENPR1-	G ATC A	Leu TIG	I Jet ATG	Val GTT	TAT
GCT	GTG	TCT	TTG	TCA	ACG	CTA	Nco Ala N GCC /	Ser	30 Leu TTA
ACA	ပ္သည	AAA	TGT	TGT	GTT	Tyr	Pro	Val	Leu
TTG	TCC	TTT	TGA	GAT	CTG	Lys AAA	Gln	Pro	Ser
TGT	TTG	GCA	ATT	CGT	CAT	-22 Met ATG	Ala GCC	Leu	Glu
TCA	CAT	GTT	AAG	TII	CII	TTG	Ala GCT	Ser TCC	Ser
2,-c	GTT	ACG	TGT	TTG	GTG	ATT	Leu	Ser	86 TCC

L	L	J
(2)
(٢	j
L	1	_

526	574	622	670	718	766
Trp	Gly GGA	Asp	Phe	120 Lys AAA	Lys AAG
Tyr	Ser	Glu GAA	Thr	Ala GCG	Lys
Ile Att	70 617 660	Thr	Leu	Asp	Ala GCT
Leu	Thr	Lys	970 000	Asp	Asp Gat
Leu CTG	Phe TTC	Val	100 Tyr TAT	Ala GCG	Asp Gac
Lys	Argo	Ser	Ser	Ser AGT	Lys
50 CCT CCT	Asp	Ser	Tyr TAT	Lega	130 Lys AAG
Ser	Pro CCT	Ile	Tyr Tat	Hind III Lys Leu Ser AAG CTT AGT	Ala GCT
Gln CAG	Val	Ser TCC	Gln	Leu	Asp GAC
Gly	G1y GGG	Leu	Gln	Val	Asp Gat
Pro	Ser	Thr	Cys	110 Leu CTG	Lys AAG
Lys	Glu	Phe TTC	Tyr	Lys	Lys AAG
Gln	60 AGG	Asp Gat	Tyr	Thr	Ala GCG
Gln	Ala	Thr	Val	G14 GGG	Ala
Tyr	Ser	G1y GGG	90 Ala GCA	Ala	Asp
Tro	Ala	Ser	CTG	61y 66T	Lys

F16. 6C

814	862	910	958	1006	1054
Pro	Thr	GIU	GAG Glu GAG	Thr	Tyr
Xho I 140 Asp Leu Glu Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro IC CTC GAG GTT CAG TTG CAG CAG TCT GAC GCT GAG TTG GTG AAA CCT	Phe	Leu CTG	AAT Asn AAT	Ser	Val GTG
150 Val G AA	Thr	GLY	14C 14C 14C	Ser	230 Ala GCA
ր 10 0	Tyr	Gln	AAA Lys Aaa	Ser	Ser
Glu G TT	Gly	180 Glu GAA	TTT Phe TTT	Lys	Asp GAT
Ala T GA	Ser	Pro	GAT Asp Gat	Asp	Glu
Asp GC GC	Ala GCT	Asn	GAT ASP GAT	210 Ala GCA	Ser
Ser T GA	Lys AAG	Gln	CC49VHP- Pro Gly Asn CCC GGA AAT	Thr	Thr
Gln G TC	160 Cys TGC	Val Lys GTG AAA	3049 614 664	Leu CTG	Leu
Gln CA	Ser	Val GTG	9 r g	Thr	Ser
ာ ၁၈ ၁၈	Ile	a Trp	190 Ser TCT	Ala GCC	Asn
61p 17	Lys	H C	Phe	Gly Lys GGC AAG	Leu
140 781 7 CA	Val GTG	Ile ATT	TAT	G14 GGC	220 Gln CAG
1 G1u G G1	Ser	Ala GCA	Gly	Lys AAG	Val GTG
X Po	Ala GCT	170 His CAT	Trp 11e TGG ATT	Phe	Tyr
Asp ic cī	G1y GGG	Asp	1rp 166	Are	Ala

2)
(2)
(_	;
Ī	ı	_

1102	1150	1198	1246	1294	1342
Ser	Ala GCT	280 116 ATT	Lys	Asn	Pro
Thr	Ala GCA	VL Asp Gac	Glu GAG	Gly GGT	Ser
G GGA	Asp	Leu	614 660	310 Ser Agt	Gln
CAA CAA	Lys AAA	Asp Gat	Val	Tyr	61y 666
661 661 661	260 Lys AAG	Lys	Ser	Leu TTA	Pro CCA
1166	Ala	Lys	Val GTG	Lec	Lys AAA
TAC	Asp	Ala	290 Pro CC1	Ser	Gln
Ala	Asp Gat	ASP	Leu	Gln	Gln
240 ATG Met ATG	Ala GCA	Asp	Ser	Ser	320 Tyr TAC
AAT Asn AAT	Ser	Lys	Ser	Ser	T T T D
1 6 C	Leu CTA	270 Lys AAA	Pro	Lys	Ala
VH49J- G Arg Ser Leu AGA TCC CTG	Ser	Ala	Ser	Cys	Leu
Arg Aga	Ser	Asp Gat	Glu	300 Ser AGC	Tyr
Thr	Val	Asp	Ser	Leu	Asn
Cys TGT	250 Thr ACC	Lys	Met	Thr	Lys AAG
Phe TTC	Val	Lys AAA	Val	Val GTT	Gln

L	L	J
(0)
`	۷.	
_	_	•
(r)
_	_	_
۱	1	
-	_	_

1390	1438	1486	1534	1582	1630	1678
Asp GAT	360 Ser AGC	TAT Tyr TAT	Leu	Lys	Asp	440 Ala GCT
Pro	Ile ATC	TAT Tyr TAT	Lys AAG	Ala	Ser	Lys AAG
Val	Ser	CAG Gln CAG	390 Leu CTG	ASP	Gln	Cys 1GC
G1y GGG	Leu	CAG Gln CAG	Val	Asp	Gln	Ser
340 Ser TCT	Thr	370 49VLCDR3+- Tyr Tyr Cys TAT TAC TGT	Leu	Lys	420 Leu TTG	Ile ATT
G1u GAA	Phe TTC	TCDE	Lys Aag	Lys	Gln	Lys AAG
Arg Agg	Asp GAT	370 #97 TYF	Thr	Ala	Val	Val GTG
Ala GCT	Thr	Val	Gly GGG	Ala	VH Glu GAG	Ser
Ser	61y 666	Ala	Ala GCT	400 As p Gac		Ala GCT
Ala GCA	Ser	Leu	Gly	Lys	Asp Gat	G13 GGG
Trp TGG	350 Gly GGA	Asp	Phe TTC	Lys	Lys	430 Pro CCT
Tyr	Ser	Glu	Thr	N18	AAA	Lys AAA
Ile	61y 660	Thr	380 Leu CTC	Asp	Ala GCA	Val GTG
Leu	Thr	Lys	Pro	ASP GAT	Asp Gat	Leu
330 Leu CTG	Phe TTC	Val GTG	TAT Tyr TAT	Eco47 III Ser Ala Asp Asp A AGC GCT GAT GAT C	410 Asp GAT	Glu
Lys AAA	Arg	Ser	AGC Ser AGC	Ecol Ser Agc	Lys AAG	Ala GCT

8/20-

_	(_
(ſ	j
ī	1	<u> </u>

1966	1918	1870	1822	1774	1726
GAT	520 Tyr TAC	Ser	Ala GCA	Asp GAT	Asn
I AGC	Ala	Thr	Thr	Asn	Gln
Nhe GCT	Met ATG	Leu CTG	Leu	470 Gly GGA	Lys
AAA	Asn	Ser AGC	Thr	Pro	Val
*** TAA	Leu	Asn AAC	Ala	Ser	177 166
Ser	N H C C C	Leu	Lys	Phe	His
530 Ser TCC	Arg Aga	Gln	61y 660	Tyr	#50 Ile ATT
Val GTC	Thr	Val	Lys	Gly	Ala
Thr	C TGT	Tyr	#80 Phe Trc	Ile	His
Val GTC	Phe	Ala	Arg	Tra	Asp
Ser	510 Tyr TAT	Thr	Glu GAG	Glu	Thr
Thr	Val GTG	Ser	Asn AAT	Leu	Phe TTC
Gly	Ala GCA	Ser	Tyr	460 G17 GGC	Thr
Gln	Ser	Ser	Lys AAA	Gln CAG	Tyr
61y 661	ASP	490 Lys AAA	Phe TTT	Glu	Gly
Tr Tr	Glu	ASP	Asp Gat	Pro	Ser

(_)
(2)
(;
Ē	1	_

5	100 1	610 80	AAA 2P 1-	AA TCC GTC AAA ACA TCA TCT TAC ATA AAG TCA CTT GGT GAT CAA SQP1- TGT AGA ATG TAT TTC AGT PENPTSEQ2- G TAT TTC AGT GAA CCA CTA GTT	TCA AGT	TCT AGA ISEQ2	ATG	ATA TAT TAT	777C 777C	AGT AGT AGT	GAA	GGT	GAT	GTT	GCI	2014	
브	ATC	ATT	GTC	AT ATC ATT GTC CGG CAA TGG TGT GGG CTT TTT TTG TTT	CAA	166	TGT	999	CIT	TTT	TTG	TTT	TCT ATC	ATC	TTT	2062	
3	GAT	CAT	GTG	AA GAT CAT GTG AAG AAA AAC	AAA	AAC	GGG AAA ATC GGT CTG CGG GAA	AAA	ATC	GGT	CTG	990	GAA	AGG	ACC	2110	
Ö	TII	TTG	TCG	GG TIT ITG ICG AAA	TCA	TAG	TCA TAG GCG AAT GGG TTG GAT TGT GAC	AAT	999	TTG	GAT	TGT	GAC	AAA	ATT	2158	
8 c	H I	BamH I	_		•											2165	

430

75 760 760

Ser AGC

Leu

Thr Act

Val

Glu Lys

915 965

Val

Ser TCA

Val GTG

Ser Leu Pro 1

Ser

382

334

F1G. 7A

Leu AGA ACG TG CL& I EGOR I 5'-C TCA TGT TTG ACA GCT TAT CAT CGA TGA ATT CCA TCA CTT CCC TCC ATT TTA ICC CCG GIG GAA ACG AGG ICA ICA III CCI ICC GAA AAA Leu TTA Ser **S**¥ GAG ACG GIT GCA TIT AAA ICT TAC ATA TAT AAT ACT TIC AAA GAC TAC Gly Leu GGA TIG Gln CAG **A**66 TAC GTG Ser ဗ္ဗဗ္ဗ ဗ္ဗဗ္ဗ ACG ATA ATA DNA AND AMINO ACID SEQUENCE OF CC49 VL-L-VH-L-VL Met Ala GCT CGT **0**00 AAA TTT Val TTC Ala GCC TGA TGT TTG AGT CGG CTG AAA GAT GTA Ala Ile ATT ATA TAT ACT AAT CAA PENPR2-Thr VL Asp Gac PENPRI- AAC TIG III CGI GAI IGI ICA AGC CAI AAC Ala Pro CCT Nco I Ala Met GCC ATG Leu Leu CTA TTG CAT CTG GTT ACG ATC TAC CCA CA Glu Lys Ala -22 Met ATG TTG TGT AAG ATT Ala TTG CTT CAT ATT CTC GTG

238

142

76

190

286

Ξ	L	_
(r	;
L	L	_

478	526	574	622	670	718	766
A140 GCC 800	Trp TGG	Gly GGA	Asp GAC	Phe	120 Lys AAA	Lys AAG
Leu A. TTG G	Tyr Ty TAC T	Ser G	Glu A	Thr P ACG T	Ala L GCG A	Lys L AAA A
TAL	ATT	270 660	Thr	Leu	Asp Gat	Ala GCT
Asn	Leu	Thr	Lys AAG	Pro CCC	ASP	Asp
Lys	Leu	Phe	Val	100 Tyr TAT	Ala	Asp Gac
	Lys	Arg	Ser AGT	Ser	Ser	Lys AAA
Asn	Pro GCT	Asp	Ser AGC	Tyr Tat	Lection	130 Lys AAG SEQ
	Ser	Pro	Ile	Tyr Tyr S TAT TAT A	Hind III Lys Leu Ser AAG CTT AGT	Ala GCT 7L(-)
Ser		Val	Ser TCC	Gln	Lea CTG	Asp Ala I GAC GCT I
Tyr	G13 GGG	Gly	Lec		Val	Asp Gat Cta
30 Leu TTA	Pro	Ser	Thr	Cys	110 Leu CTG	Lys AAG TTC
CTT		Glu	Phe	Tyr	Lys	Lys AAG TTC
Ser	Gln	60 Arg AGG	Asp Gat	Tyr TAT	Thr	Ala GCG CGC
Gln	Gln	Ala GCT	Thr	Val GTT	GIY	Ala GCT CGA
Ser	Tyr	Ser	GLY	90 A1a GCA	Ala GCT	Asp GAT CTA
5 0	r 0 0 0	CA CA	60	9 H	217	AAG TTC

F16. 70

814	862	910	958	1006	1054	1102
Pro	Thr	Glu	200 GAG Glu GAG	Thr	Tyr	Ser
Lys AAA	Phe	Leu CTG	AAT Asn AAT	Ser	Val GTG	Thr
150 Val GTG	Thr	G1 y	TAC Tyr TAC	Ser	230 Ala GCA	G Gly GGA
Leu TTG	Tyr	Gln CAG	AAA Lys Aaa	Ser	Ser	CAA CAA
Glu	G13 GGC	180 Glu GAA	rrr Phe rrr	Lys AAA	Asp Gat	667 614 667
Ala GCT	Ser	Pro	GAT ASP GAT	ASP	Glu	776 777 766
Asp GAC	Ala	Asn	GAT ASP GAT	210 Ala GCA	Ser	TAC Tyr TAC
Ser	Lys	Gln	CC49VHP- Gly Asn GGA AAT	Thr	Thr	GCC Ala GCC
Gln	160 Cys TGC	Lys	50497 6014 668	Leu Cic	Leu	240 ATG Met ATG
Gln	Ser	Val GTG	000	Thr	Ser	AAT Asn AAT
Leu	Ile	Tro TGG	190 Ser TCT	Ala	Asn	J- Cre Cre
Gln	Lys	His	Phe	Lys	Leu	VH49J- G Ser Leu TCC CTG
140 Val GTT	Val	Ile	Tyr	Gly	220 Gln CAG	Are
VH I Glu GAG	Ser	Ala	Gly GGA	Lys	Val GTG	Thr
Xho Crc	Ala	170 His CAT	Ile	Phe	Tyr	Cys
Asp	G1y GGG	Asp GAC	Tro	Arg	Ala	Phe

1 $_{3}$ / $_{2}$ 0 SUBSTITUTE SHEET (RULE 26)

F16. 71

1150	1198	1246	1294	1342	1390	1438	1486
Ala GCT	280 Val GTT	Val	IIB	Tyr	GIY	360 Gln CAG	Arg Aga
Ala A GCA G	VH Glu GAG	Ser	Ala	GIY	Lys AAG	Val	Thr
ASP A	CHI	Ala GCT	310 H1s CAT	ILO ATT	Phe	Tyr	Cys
Lys A	Asp Gat	61y 666	Asp	11 10 00	Arg Agg	Ala GCC	Phe TTC
260 Lys L AAG A	Lys	Pro	Thr	GAA	340 G1u GAG	Thr	Tyr
Ala L GCA A	Lys	Lys AAA	Phe	CTG	Asn AAT	Ser	Val GTG
Asp A	Ala	290 Val GTG	Thr	614 660	Tyr	Ser	370 Ala GCA
Asp A Gat G	ASP	Leu TTG	TAC	Gln	Lys	Ser	Ser
Ala A GCA G	Asp Gat	Glu	G13 GGC	320 Glu GAA	Phe	Lys Aaa	Asp Gat
Ser A	Lys	Ala GCT	Ser	Pro CCT	Asp Gat	Asp GAC	Glu
Leu S	270 Lys AAA	Asp	Ala GCT	Asn AAC	Asp GAT	350 Ala GCA	Ser
Ser I	Ala	Ser	Lys	Gln	Asn	Thr	Thr
Ser S	Asp Gat	Gln	300 Cys 16C	Lys	Gly GGA	Leu	Leu
Val S	Asp	Gln	Ser	Val	87.0 0.00	Thr	Ser
250 Thr V	Lys AAA	Leu	Ile Att	Trp	330 Ser TCT	Ala GCC	Asn AAC
Val 1 GTC A	Lys	Gln	Lys	HIS	Phe	Lys	Leu


F16. 71


_						_		
1870	1918	1966	2014		2062	2110	2158	2165
Thr	520 Leu CTC	GAT	GCT		TTT	ACC	ATT	
Lys AAG	Pro	I AGC	CAA	GTT	ATC	AGG	AAA	
Val	Tyr TAT	Nhe	GAT	CTA	TCT	GAA	GAC	
Ser AGT	Tyr Ser Tyr TAT AGC TAT	AAA	GGT	CCA	TIT	990	TGT	
500 Ser AGC	Tyr TAT	*** TAA	CTT	GAA	TTG	CTG	GAT	
Ile	Tyr TAT	II Lys AAG	TCA	AGI	TTT	GGT	TTG	
Ser	Gln	Ari Leu CTT	AAG	110	CII	ATC	999	
Leu	Gln CAG	Val GTG	ATA	TAT	999	AAA	AAT	
Thr	Cys	Leu CTG	TAC	ATG 2- G	TGT	000	gcg	
Phe TTC	Tyr	Lys	TCT	r AGT AGA ATG PENPTSEQ2- G	TGG	AAC	TAG	
Asp Gat	510 Tyr TAT	Thr	TCA	AGT PENP1	CAA	AAA	TCA	
Thr	Val GTT	G13 GGG	AC	i S	990	AAG	AAA	
Gly GGG	Ala GCA	Gly Ala GGT GCT	GTC AAA	2P 1-	GIC	GTG	TCG	•
Ser	Leu	Gly	GTC	χ Σ	ATT	CAT	TTG	C-3
490 G1y GGA	Asp GAC	Phe TTC	TCC		CAT ATC ATT GTC	GAT	TTT	BamH I CGG ATC C-3
Ser	G1u GAA	Thr	GAA		CAT	AAA	ຽຽຽ	Bai


F16. 7E


1534	1582	1630	1678	1726	1774	1822
Ser	Asp	Gln	440 Ser AGC	Tyr TAC	Ile ATT	Gly
Val	Asp gac	Ser	Leu	Asn AAC (2(-)	Leu	Thr
Thr	Lys AAA	Met	Thr	Gln Lys Asn CAA AAG AAC 49LFR2(-)	#70 Leu CTG	Phe
Val GTC	Lys	Val	Val	Gln CAA	Lys	Arg
Ser	Ala	420 116 ATT	Lys	Asn AAT	Pro	Asp Gat
Thr	Ala	VL Asp Gac	Glu GAG	Gly GGT	Ser	Pro
Gly	Asp	Leu	GLY	450 Ser Agt	Gln	Val GTC
Gln	Lys	Asp GAT	Val	Tyr	G14 GGG	61y 666
Gly	koo Lys AAG	Lys	Ser	Leu TTA	Pro	480 Ser TCT
Trp	Ala GCA	Lys	Val GTG	Leu	Lys	Glu
Tyr	Asp	Ala	#30 Pro CCT	Ser	Gluca	Arg
Ala GCC	Asp Gat	Asp	Leu	Gln	Glu	Ala GCT
Met ATG	Ala GCA	Asp Gat	Ser		460 Tyr TAC	Ser
Asn AAT	Ser	Lys	Ser	Ser	177 166 A CC	Ala GCA
Leu	Leu	4 10 Lys AAA	Pro	Lys	A18 GCC CGG	dr 166
Ser	Ser	Ala	Ser	Cys	Lec TTG	Tyr

i1 6 / 2 0 SUBSTITUTE SHEET (RULE 26)









2 0 / 2 0 SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

Intern al Application No PCT/US 93/12039

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C12N15/13 C07K15/28 A61K39/395 C12N15/62 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 5 C12N C07K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Category * X WO,A,91 19739 (CELLTECH LIMITED) 26 1,5 December 1991 2-4,6 Y see example 1 3,6 Y CANCER RESEARCH vol. 52, no. 12 , 15 June 1992 , PHILADELPHIA, PA, USA pages 3402 - 3408 T.YOKATA ET AL. 'Rapid tumour penetration of a single-chain Fv and comparison with other immunoglobulin forms' see page 3403, column 1, paragraph 4 Patent family members are listed in annex. Further documents are listed in the continuation of box C. Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-"O" document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled other means in the art. document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search **27 -**04- 1994 25 March 1994 Authorized officer Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Cupido, M Fax: (+31-70) 340-3016

1

INTERNATIONAL SEARCH REPORT

Intern: ul Application No
PCT/US 93/12039

		PC1/US 93	/ 12039
C.(Continua Category	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
Y	BIOCHEMISTRY vol. 30, no. 42, 22 October 1991, EASTON, PA US pages 10117 - 10125 M.W.PANTOLIANO ET AL. 'Conformational stability, folding and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escherichia coli' cited in the application see page 10120, column 1, paragraph 2		2,4
X	EP,A,O 506 124 (TANOX BIOSYSTEMS, INC.) 30 September 1992 see example 4		1,5
Ρ,Χ	WO,A,93 11161 (ENZON, INC.) 10 June 1993 see figure 19A		1,3-6
			·

1

INTERNATIONAL SEARCH REPORT

information on patent family members

Intern d Application No
PCT/US 93/12039

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9119739	26-12-91	AU-A- EP-A- GB-A- JP-T-	7983191 0486652 2250995 5502039	07-01-92 27-05-92 24-06-92 15-04-93
EP-A-0506124	30-09-92	AU-B- AU-A- JP-A-	640863 1299292 5117164	02-09-93 15-10-92 14-05-93
WO-A-9311161	10-06-93	AU-A-	3178993	28-06-93

Form PCT/ISA/210 (patent family annex) (July 1992)